MDS News Highlights

ASH 2012 – MDS FOUNDATION SYMPOSIUM

■ Myelodysplastic Syndromes: Current Understanding and Management Approaches
Effective management of MDS requires understanding of underlying disease-specific abnormalities as well as patient-related features. These issues as well as current standard and recent novel therapeutic advances for MDS patients will be discussed.

REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM FOR MDS

The manuscript describing the Revised IPSS (IPSS-R) for MDS is available now in the September 23, 2012 issue of Blood (vol. 120, p. 2454).

FROM THE GUEST EDITOR’S DESK

■ Recent Molecular Abnormalities in MDS
Presented by Luca Malcovati, MD

TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>FROM THE GUEST EDITOR’S DESK</td>
<td>2</td>
</tr>
<tr>
<td>REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM FOR MDS</td>
<td>3</td>
</tr>
<tr>
<td>Meeting Highlights/Announcements</td>
<td></td>
</tr>
<tr>
<td>ASH 2012: MDS FOUNDATION SYMPOSIUM</td>
<td>6</td>
</tr>
<tr>
<td>37th Annual ONS Congress</td>
<td>8</td>
</tr>
<tr>
<td>12th International MDS</td>
<td>14</td>
</tr>
<tr>
<td>MDS Resources: Literature Highlights</td>
<td>16</td>
</tr>
<tr>
<td>News Briefs</td>
<td>18</td>
</tr>
<tr>
<td>From The Foundation</td>
<td>19</td>
</tr>
<tr>
<td>Patient Initiatives</td>
<td></td>
</tr>
<tr>
<td>Worldwide Patient Forums/Support Groups</td>
<td>20</td>
</tr>
<tr>
<td>Patient Contributions</td>
<td>23</td>
</tr>
<tr>
<td>Nursing in MDS</td>
<td>28</td>
</tr>
<tr>
<td>MDS Centers of Excellence</td>
<td>29</td>
</tr>
<tr>
<td>Information on Clinical Trials</td>
<td>32</td>
</tr>
<tr>
<td>Contributions to the Foundation</td>
<td></td>
</tr>
<tr>
<td>Thank You</td>
<td>33</td>
</tr>
<tr>
<td>In Memoriam</td>
<td>35</td>
</tr>
<tr>
<td>Living Endowments</td>
<td>43</td>
</tr>
<tr>
<td>MDS Foundation Board of Directors</td>
<td>44</td>
</tr>
</tbody>
</table>

www.mds-foundation.org
Recent Molecular Abnormalities in MDS

Luca Malcovati, MD
Department of Hematology/Oncology
University of Pavia School of Medicine
San Matteo Hospital, Pavia, Italy

Myelodysplastic syndromes (MDS) are a heterogeneous group of hematologic disorders characterized by ineffective hematopoiesis, peripheral cytopenias and increased risk of evolution into acute myeloid leukemia (AML).1 MDS are included in the category of myeloid neoplasms in the World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues, together with myeloproliferative neoplasms (MPN), myelodysplastic/myeloproliferative neoplasms (MDS/MPN), and AML.2

MDS represent some of the most common hematologic malignancies in Western countries. They occur mainly in elderly people with a median age at diagnosis of 70–75 years. Incidence is approximately 5 per 100,000 persons per year in the general population, but increases to 20–50 per 100,000 persons per year over the age of 60.3 Considering the progressive aging of the population in Western countries, the number of MDS patients is destined to increase over the next decades, making MDS one of the most challenging issues for hematologists and health care providers in the near future.

MDS are characterized by clonal proliferation of hematopoietic cells that differentiate inefficiently as a result of excessive apoptosis of hematopoietic precursors. The bone marrow is generally hypercellular and several morphological abnormalities are observed in one or more cell lineages, whereas peripheral blood cells are variably reduced. With time, differentiation and maturation of hematopoietic cells are progressively impaired, and there is an increasingly high risk of evolution to overt AML.

Unravelling the Molecular Basis of MDS

Until recently, the molecular basis of MDS had remained elusive. Recurrent chromosomal abnormalities, in particular deletions or amplifications of large chromosomal segments, were reported in approximately 50% of MDS patients using standard chromosomal banding analysis. Among the most frequent are −5/del(5q), −7/del(7q), trisomy 8, del(20q), and a complex karyotype.4 However, the last few years have seen important progress in this field.

Gene Haploinsufficiency

Deletions of the long arm of chromosome 5 are the most frequent single chromosomal abnormality in MDS. Patients with isolated del(5q) may present a peculiar clinical phenotype, first described by Van den Berghe et al. in 1974 and defined as the 5q− syndrome.5 Patients with the 5q− syndrome have a macrocytic anemia, with normal or elevated platelet counts associated with hypolobulated megakaryocytes in the bone marrow.

The determination of the commonly deleted region located at 5q33 was the first step towards clarifying the molecular basis of MDS.6 Sequencing and high-resolution techniques failed to identify mutations in the commonly deleted region, whereas a functional screening of all these genes by an RNA-mediated interference-based approach determined that haploinsufficiency of RPS14, encoding a component of the 40S ribosomal subunit, is likely the cause of the erythropoietic defect in the 5q− syndrome.7 Interestingly, heterozygous inactivating mutations in RPS19 and other ribosomal proteins were previously described in Diamond Blackfan Anemia, an inherited bone marrow failure syndrome.

Subsequent investigations showed that ribosomal deficiency in 5q− syndrome results in activation of p53 and defective erythropoiesis.8 Other data from mouse models suggested that haploinsufficiency of the microRNA genes miR-145 and miR-146a may contribute to the dysregulated megakaryopoiesis and thrombocytosis seen in this disorder.9

Acquired Somatic Mutations

Acquired somatic mutations have been recently detected in several genes. The genes mutated in MDS can be classified according to the function of the proteins they encode. The most commonly mutated class of genes in MDS encode splicing factors (SF3B1, U2AF1/U2AF35, ZRSR2, SRSF2, SF3A1, PRPF40B, U2AF2/U2AF65, and SF1).10,11 Genes encoding epigenetic regulators are also commonly mutated in MDS, including TET2, DNMT3A, IDH1/2, ASXL1, and EZH2.12,13 Transcription factors involved in hematopoietic progenitor cells are also mutated, including RUNX1 and ETV6.14 Mutations that lead to activated tyrosine kinase signaling occur in the genes encoding JAK2, NRAS/KRAS, PTPN11, MPL, and CBL.15 Mutations of the tumor suppressor gene TP53, involved in DNA damage repair pathway, are also common.16

Recently, two groups have published independent reports of mutations involving multiple components of the RNA splicing machinery. Somatic mutations of SF3B1, a gene encoding subunit 1 of the splicing factor 3b protein complex, were first described by investigators from the Chronic Myeloid Disorders Working Group (CMD-WG) of the International Cancer Genome Consortium.17 Using massively parallel sequencing, the CMD-WG investigators found somatic mutations of SF3B1 in six of eight patients with refractory anemia with ring sideroblasts. A targeted resequencing of the gene in hematologic malignancies and solid tumors showed SF3B1 mutations in approximately 30% of patients with MDS, and 20% of patients with myelodysplastic/myeloproliferative neoplasm (MDS/MPN).
The gene was also found to be mutated in smaller proportions of patients with other types of tumor.

In patients with MDS, a close relationship was found between ring sideroblasts and SF3B1 mutations. Interestingly, a high prevalence of SF3B1 mutations was found in patients with 15% or greater bone marrow ring sideroblasts as well as in those with less than 15%. SF3B1 mutations were associated with downregulation of key gene networks, including core mitochondrial pathways. The association between SF3B1 mutation and ring sideroblasts was confirmed across all the myeloid neoplasms, including myeloproliferative neoplasms (MPN) and MDS/MPN. In fact, among MDS/MPN, a high prevalence of SF3B1 mutations was also observed in patients with RARS associated with marked thrombocytosis. In addition, somatic mutations of SF3B1 were also observed in a small fraction of patients with primary myelofibrosis, and in all cases sideroblasts were detected in the bone marrow.

In the same period, the CMD-WG described SF3B1 mutation in MDS with ring sideroblasts. Yoshida et al. performed whole exome sequencing in various subtypes of MDS and described mutations in multiple components of the spliceosome, including U2AF1, ZRSR2, and SRSF2, mainly in myeloid disorders without ring sideroblasts. In particular, approximately one-third of patients with chronic myelomonocytic leukemia (CMML) had a somatic mutation of SRSF2. Although little is currently known about the downstream processes that are affected by spliceosome mutations, these data clearly suggest that genes encoding core components of the RNA splicing machinery play a major role in MDS pathophysiology.

Epigenetic modifications mediate changes in gene expression through chemical modifications of DNA, including methylation of dinucleotides, and methylation or acetylation of histone proteins. Aberrant DNA methylation has been implicated in the pathogenesis of MDS and AML, and aberrant methylation profiles were observed in both disorders. In addition, hypomethylating agents, such as azacitidine and decitabine, are effective in the treatment of MDS, and are indeed associated with changes in genome-wide methylation patterns in bone marrow cells of treated patients. However, no key genes or methylation signatures that may predict response to therapy have been recognized.

TET2 mutations have been identified in approximately 25% of patients with MDS. These mutations cause a loss of function of the TET2 enzyme that converts 5-methylcytosine to 5-hydroxymethylcytosine. Additional evidence suggests that TET2 is important for normal myelopoiesis, and that disruption of TET2 enzymatic activity favors myeloid tumorigenesis. Mutations in DNA methyltransferase 3A (DNMT3A) were first discovered by whole genome sequencing in AML cases, and subsequently identified in 5–10% of MDS patients. DNMT3A adds a methyl group to the 5’ position of CpG dinucleotides. Experiments in mice showed that disruption of DNMT3A results in impaired hematopoietic differentiation but not in hematologic malignancy, suggesting that transformation requires co-operating mutations.

Mutations in genes involved in the regulation of histone function were also recognized, including EZH2, and ASXL1. Mutations in ASXL1 have been found in 10–15% of MDS patients. Loss of function of ASXL1 leads to increased expression of HOX genes and defective differentiation of hematopoietic progenitors.
mutations in EZH2 were detected in 2–6% of MDS patients. EZH2 is part of a methyltransferase responsible for methylation of histone 3. Inactivating mutations in members of this complex result in activated gene expression.13

Additional studies will be required to clarify the specific mechanisms by which these mutated genes contribute to MDS pathogenesis and the patterns of association between mutations. Further studies will also help us understand the clinical implications of these mutations in terms of disease course, treatment response and survival.

**Integrating Somatic Mutations in the Diagnosis and Classification of MDS**

The current diagnostic approach to MDS includes morphological analysis to detect abnormalities of peripheral blood cells and hematopoietic precursors, bone marrow biopsy to evaluate marrow cellularity and topography, and cytogenetics to detect clonal chromosomal abnormalities. The combination of marrow dysplasia and clonal cytogenetic abnormalities allows a conclusive diagnosis of MDS to be made, but this is found in only a fraction of patients. In many instances, the diagnosis of MDS is exclusively based on clinical and morphological criteria, and may be particularly difficult in patients who do not have robust morphological markers, such as ring sideroblasts or excess of blasts.

A major effort should be made to identify novel diagnostic tools that may improve the accuracy of MDS diagnosis.

Although most of the genes recurrently mutated in MDS can be detected in different myeloid neoplasms and are not, therefore, specific for MDS, they may be a valuable means of obtaining evidence of a clonal disorder in patients with suspected MDS. In a recent comprehensive report, 52% of patients with normal cytogenetics had at least one point mutation.14 These figures are even higher for mutations of the genes encoding for splicing factors.

Recent studies in chronic myelomonocytic leukemia reported cytogenetic aberrations in approximately 20% of patients, whereas a comprehensive mutation analysis revealed that 93% of patients with this disorder carried at least one somatic mutation.22

Although, at this stage, the screening of such molecular defects cannot be recommended on a routine basis, the spread of massive genotyping methods will soon make it possible for clinicians to detect a broad range of cytogenetic aberrations in peripheral blood at a reasonable cost, making it easier to confirm diagnosis in patients with suspected MDS.

**Genotype-phenotype Correlations: The Foundation Stone for a Molecular Classification of MDS**

In a group of disorders classified on the basis of morphological criteria, identifying specific associations between genotype and disease phenotype is essential for recognizing disease entities according to distinctive genetic profiles.

This genotype-phenotype correlation in MDS is illustrated by the 5q- syndrome. The typical hematologic phenotype includes macrocytic anemia, normal or elevated platelet count with hypolobated megakaryocytes, and a low rate of progression to AML. In 2001, the WHO classification recognized MDS with isolated del(5q) as a distinct disease entity. Although cases classified in this subtype show different morphological features, and most patients do not have the specific combination of signs that constitute the 5q-syndrome, this represents the first subtype of MDS defined by a genetic abnormality.2

A major step forward in genotype-phenotype correlation has been the identification of somatically acquired mutations in SF3B1 in MDS patients with ring sideroblasts. The specific association between SF3B1 and ring sideroblasts was unequivocally demonstrated by the analysis of a subgroup of patients in whom an accurate quantitative enumeration of ring sideroblasts was performed using recently established consensus criteria, irrespective of WHO categories. Overall, the SF3B1 mutation status had a positive predictive value for disease phenotype with ring sideroblasts of 97.7%, while the absence of ring sideroblasts had a negative predictive value for SF3B1 mutation of 97.8%. The causal relationship between SF3B1 mutation and ring sideroblasts was also supported by the significant association between the SF3B1 mutant allele burden and the percentage of ring sideroblasts.17

Although several issues still remain to be clarified, these observations are important for MDS classification. The RCMD-RS category was created in the 2001 WHO classification of myeloid neoplasms, but was then incorporated into the RCMD category in the updated 2008 WHO classification. These findings suggest that RCMD and RCMD-RS should instead be considered as separate categories, or a distinction should at least be made between patients with wild-type or mutated SF3B1.

In addition, the observation that SF3B1 mutations were found in patients with 15% or greater bone marrow ring sideroblasts as well as in those with less than 15%, suggests that this threshold, first adopted by the FAB and then by the WHO classification, does not recognize separate entities, and that, instead, the proportion of ring sideroblasts in the bone marrow appears to be a continuum of a unique biological process.

**Prognostic Relevance of Somatic Mutations in MDS: Toward Next-Generation Prognostic Scoring Systems**

Myelodysplastic syndromes are a heterogeneous group of disorders ranging from indolent conditions with a near-normal life expectancy to forms close to AML. A risk-adapted treatment strategy is mandatory for conditions showing such a highly variable clinical course. Prognostic assessment in patients with MDS is currently based on stratification systems that combine multiple clinical and hematologic variables, including the International Prognostic Scoring System (IPSS),24 which
has been the reference for clinical decision-making as well as for design and analysis of clinical trials in these disorders, the WHO classification-based prognostic scoring system (WPSS), the M.D. Anderson Prognostic Scoring System (MPSS) and, more recently, the revised IPSS.

The available evidence clearly indicates that a greater understanding of the molecular basis of MDS may improve our ability to stratify the prognosis of patients with MDS.

Mutations in several genes have been reported to influence overall survival and risk of disease progression in MDS. Recently, a comprehensive analysis of patients with MDS identified mutations in five genes (ASXL1, RUNX1, TP53, EZH2, and ETV6) that were significantly associated with poor survival after adjustment for demographic factors and IPSS risk groups. A prognostic model was then developed to integrate the mutational analysis results into the IPSS, by including a variable for mutations in one or more of these five prognostic genes. More recently, SF3B1 mutations were found to be independent predictors of favorable clinical outcome after adjusting for IPSS or WPSS.

Taken together, this evidence suggests that the integration of somatic mutations in next-generation prognostic scoring systems is resulting in more accurate stratification of individual patient risk, and further refines clinical decision making in MDS.

**Conclusion**

Our understanding of the molecular basis of MDS is improving rapidly. The identification of genetic defects and the recognition of their association to clinical features and outcome is going to have a major impact on our approach to MDS patients. The more widespread use of massive genotyping technology will soon enable us to detect a broad range of gene mutations at a reasonable cost. This will make diagnosis of these disorders easier, and will improve our assessment of individual patient risk, the selection of appropriate therapy and the monitoring of response to treatment.

**References**

Meeting Highlights and Announcements

Join Us for a FREE CME/CE Breakfast Program

Myelodysplastic Syndromes: Current Understanding & Management Approaches

FRIDAY
December 7, 2012
7:00AM Breakfast & Registration
7:30 – 11:00AM Presentation

Georgia World Congress Center
Sidney J. Marcus Auditorium
285 Andrew Young International Blvd., Atlanta, GA

TARGET AUDIENCE:

This activity is intended for physicians, oncology nurses, nurse practitioners, physician assistants, and other health care professionals interested in the treatment and management of patients with Myelodysplastic Syndromes.

OUTCOMES OBJECTIVES:

Upon completion of this course, the participant will be better able to:

- Discuss underlying pathogenetic molecular lesions and constitutional predispositions in MDS patients.
- Describe the connection between patients' comorbidities, treatments and clinical outcomes.
- Identify potentially novel agents being evaluated in clinical trials for patients not responding to standard therapy.
- Describe the current status of and indications for reduced intensity conditioning and umbilical cord blood as approaches for HSCT in MDS patients.
- Develop insight into the patients' perspectives of the impact of the disease and its treatment on their quality of life.
- Apply evidence-based interventions in the care of the MDS patient for better outcomes.

FUNDING:

Supported by educational grants from: Celgene Corporation, Amgen Inc. and Oncorevive Therapeutics, Inc.

PURPOSE:

Effective management of MDS requires understanding of underlying disease-specific abnormalities as well as patient-related features. These issues as well as current standard and recent novel therapeutic advances for MDS patients will be discussed.

FACULTY

Neal S. Young, MD, MACP
Chief, Hematology Branch of the National Heart, Lung and Blood Institute

Timothy Grubbert, MD
Associate Professor of Medicine, Oncology Division, Stem Cell Biology Section, Washington University, Saint Louis, MO

Theo de Witte, MD, PhD
University Medical Center, Nijmegen St. Radboud Nijmegen, The Netherlands

Alan F. List, MD
Professor of Oncology and Medicine, Moffitt Cancer Center
University of South Florida, Tampa, FL

Mary M. Horowitz, MD, MS
OBRMTR, Medical College of Wisconsin, Milwaukee, WI

DISCLOSURES:

Faculty disclosures will be provided on the first page of the program syllabus.

ACCREDITATION:

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Foundation for Care Management (FCM) and The Myelodysplastic Syndromes Foundation. FCM is accredited by the ACCME to provide continuing medical education for physicians.

FCM designates this educational activity for a maximum of 3.5 AMA PRA Category 1 credits™. Physicians should only claim credit commensurate with the extent of the participation in the activity.

The Foundation for Care Management is an approved provider of continuing nursing education by the Washington State Nurses Association Continuing Education Approval & Recognition Program (CEARP), an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.
PLAN TO ATTEND: ASH 2012 SYMPOSIUM

Myelodysplastic Syndromes: Current Understanding and Management Approaches

December 7, 2012 • Georgia World Congress Center

AGENDA

PROGRAM OVERVIEW
Effective management of MDS requires understanding of underlying disease-specific abnormalities as well as patient-related features. These issues as well as current standard and recent novel therapeutic advances for MDS patients will be discussed.

7:30 am – 7:40 am
■ Program Overview and Objectives
Stephen D. Nimer, MD
Sylvester Comprehensive Cancer Center
University of Miami

Advances in Understanding Disease Pathogenesis

7:40 am – 8:15 am
■ Bone Marrow Failure in MDS: Role of Abnormal Telomere Dynamics
Neal S. Young, MD, MACP
NHLBI, NIH

8:15 am – 8:50 am
■ Somatic Mutations in MDS: Insight into their Prognostic and Biological Importance
Timothy Graubert, MD
Washington University

Therapeutic Advances

8:50 am – 9:25 am
■ Impact of Co-Morbidities and Treatment in Lower Risk MDS: Interim Results from the EU MDS Registry
Theo de Witte, MD, PhD
University of Nijmegen

9:25 am – 10:00 am
■ Biomarker-Directed Treatment Approaches for MDS
Alan F. List, MD
Moffitt Cancer Center

10:00 am – 10:35 am
■ Progress in Reduced Intensity Hematopoietic Stem Cell Transplantation in MDS
Mary M. Horowitz, MD, MS
Medical College of Wisconsin, CIBMTR

10:35 am – 11:00 am
■ Questions/Answers/Discussion

Stay Connected...

Follow us on:

Get Involved! Join the MDSF Development Committee!
The MDS Foundation is seeking members to join our Development Committee. Whether your contribution is time, skills, funds, or ideas you can make a difference! For more information contact Tracey Iraca at tiraca@mds-foundation.org or call 800.637.0839.

Support the MDSF!
Please make a tax-deductible donation today. Kindly use the enclosed donation envelope or go to www.mds-foundation.org to make your donation.

Thank you for your continued support!

Sign up to volunteer!
If you are interested in helping out in the MDS Foundation office or in attending events as a representative of the MDSF, please call us at 800-MDS(637)-0839.

Thank You to Our Pharmaceutical Supporters

We would like to thank our pharmaceutical supporters for their commitment to the Foundation and its work. They have contributed in the form of educational grants, which maintain not only this newsletter but also the development of continuing medical education programs, and the dissemination of patient information.
The Myelodysplastic Syndromes: Challenges and Strategies for Effective Outpatient Management

Educational Symposium
Held in New Orleans, LA

The MDS Foundation was pleased to participate in this year’s Oncology Nursing Society (ONS) annual meeting held in conjunction with its 37th Annual Congress on May 3, 2012. More than 300 nurses from across the country joined us to learn more about MDS and its treatments.

Our distinguished faculty included 4 illustrious members of our Nurse Leadership Board: Sandra E. Kurtin, Jean A. Ridgeway, Jayshree Shah, and Sara M. Tinsley. Our presenters provided the oncology nursing professional with the tools to assist patients and their families in meeting the challenge of living with MDS. Learning objectives imparted by our presenters included recent advances in strategies for the treatment of MDS from prognosis to treatment; practical tools for effective management; web-based resources for patients and nurses; as well as information developed from our Patient and Family Forums that have been held around the world which formed the basis for the presentation on patient and family support throughout the continuum of care.

During this congress the International Nurse Leadership Board for the MDS Foundation introduced a supplement to the Clinical Journal of Oncology Nursing which incorporates an update on the science of MDS, practical tools for clinical management of MDS including iron overload, a discussion of quality of life in the patient living with MDS, and a review of strategies and resources for support. Copies of this CJON Supplement are available upon request from the MDS Foundation and can also be accessed online at http://www.mds-foundation.org/cjon-supplement/.

On behalf of the MDS Foundation and our Board of Directors, thank you for joining us for our recent Satellite Symposium:
The Myelodysplastic Syndromes: Challenges and Strategies for Effective Outpatient Management

Laura J. Pinchot, BA

At A Glance

Myelodysplastic syndromes are a category of incurable malignancies that affect mainly older adults. Cytogenetic testing and advances in targeted therapies have provided a means to extend and improve the quality of life for these patients. However, patient education and overcoming barriers, such as ageism, complex and expensive treatment regimens, and adverse events, are critical to ensuring that patients with a myelodysplastic syndrome can fully benefit from evolving therapy options.

Myelodysplastic syndromes are a class of incurable diseases that originate in the bone marrow. The disease processes are quite complex and often difficult for healthcare professionals to articulate to patients and family caregivers. Sandra E. Kurtin, RN, MS, AOCN®, ANP-C, simplified the process by comparing myelodysplastic syndromes to a “broken factory.” This group of disorders is associated with the bone marrow’s inability to produce healthy leukocytes, erythrocytes, and platelets. Myelodysplastic syndromes are malignant processes that can be a precursor for acute myeloid leukemia (AML). Although no complete cure is currently available, treatments are available to support patient health for months to several years after diagnosis.

Kurtin noted that nurses must embrace the fact that treatment selection for myelodysplastic syndromes is moving toward molecular-driven models. The complexity of disease and treatment can be difficult for even seasoned health professionals to grasp, which poses a challenge for patient and family education.

Cytogenetic Evaluation

Jean A. Ridgeway, MSN, APN, NP-C, AOCN®, reported that mapping the pathophysiology of this class of hematologic diseases has come a long way since they were first classified in the 1970s. Early classification models, including the French-American-British (FAB) classification in 1976 and the World Health Organization’s late-1990s revision of this system focused on cell morphology and myeloblast (blast) counts. These systems describe the disease progression based on extent of refractory anemia and increase in blasts within the marrow.

Ridgeway noted that, also in the 1990s, advances in genetic research allowed clinicians to move toward a cytogenetic evaluation of myelodysplastic syndromes, and this shift in focus greatly enhanced the understanding of the disease process and treatment effects. In addition to the previously defined parameters of cell morphology, researchers discovered that these syndromes involve multiple cytogenetic defects. This discovery has allowed clinicians to use cytogenetics to drive diagnosis, prognosis, and treatment selection (Vardiman et al., 2009; Westers et al., 2011).

Conventional metaphase cytogenetic analysis is the gold standard for analyzing karyotypes associated with myelodysplastic diseases. This process uses an aspirated sample of bone marrow to examine 20 cells that are in the metaphase stage of cell division. Clinicians are then able to map the malignant defects within chromosomes. One drawback to the process is that the cells must be in active cell division because the errors are not apparent when this process is used on non-dividing cells.

Emerging technologies are overcoming limitations to metaphase cytogenetic analysis. For example, use of the single nucleotide polymorphism (SNP, pronounced “snip”) array analysis is able to identify abnormalities in non-dividing cells. In addition to helping in diagnosis and prognosis, the SNP array also can track response to treatment, particularly therapies that target the TET2 and TP53 genes (Garcia-Manero, 2010; Gondek et al., 2008; Graubert, 2011; Maciejewski & Mufti, 2008; Tiu, Visconte, Traina, Schwandt, & Maciejewski, 2011).

Flow cytometry is another emerging technology that may be useful in identifying prognostic features of myelodysplastic syndromes. This technology analyzes cell receptor and internal protein expression. The clinician can use this to evaluate cells from both qualitative and quantitative perspectives. Although flow cytometry has potential uses, studies indicate that standardization and refinement of quantification measures is needed (Vardiman et al., 2009; Westers et al., 2011).

Emerging technologies such as flow cytometry and SNP array analysis are helping researchers study potential targeted therapies that can be tailored to a patient’s specific genetic makeup. Studies are under way to identify novel agents and targets in addition to TET2 and TP53 (Bejar, Levine, & Ebert, 2011; Kurtin, 2011; Tiu et al., 2011).

Comprehensive Prognostic Indicator

The International Prognostic Scoring System (IPSS) takes variables from cytogenetic evaluation and cell morphology indicators identified by early classification systems (e.g., cytopenias and number of bone marrow blasts) to create a comprehensive score to predict survival. Patients’ scores are then placed in four risk categories: low, intermediate-1, intermediate-2, and high. Low-risk patients are expected to live 5.7 years, intermediately-risk patients have a
prognosis of 1.2–2.5 years, and high-risk patients are expected to live only a few months (0.4 years) (Greenberg et al., 2011).

Ridgeway noted that IPSS also serves to help clinicians to form a treatment strategy. In low-risk patients, the priorities are to manage cytopenias and their associated symptoms by administering packed red blood cells and thrombopoietin receptor agonists, as well as erythropoiesis-stimulating, immunosuppressive, and immunosuppressive agents (Ridgeway, Fechter, Murray, & Borràs, 2012). Prolonging survival is the focus of treating high-risk patients. These patients typically receive hypomethylating agents. Also, the only known “cure” for myelodysplastic syndromes is allogeneic hematopoietic stem cell transplantation; therefore, patients who fall into the high-risk category should be evaluated as potential candidates for transplantation (Ridgeway et al., 2012). Ridgeway and Kurtin both hesitated to use the word “cure” because myelodysplastic syndromes behave differently than other malignancies in that stem cell transplantation may not offer a complete response.

**Complete Patient Care**

Although the IPSS indicator is a handy tool that helps determine treatment strategy and risk, Kurtin noted that these prognostic categories were determined before current treatments were available. Therefore, high-risk patients have a prognosis of only a few months without treatment. The implications of this are that clinicians must identify and administer treatment quickly once a myelodysplastic syndrome is diagnosed.

In addition, Kurtin noted that although this is a disease that occurs in mostly older adults with the average age at diagnosis being aged 73, chronological age should not be the only indicator of treatment planning and prognosis evaluation. Performance status, frailty (failure to thrive), and comorbidities also should be considered (Balducci & Exermann, 2000; Pal, Katheria, & Hurria, 2010). Kurtin illustrated this point by noting that the average life expectancy for a 75-year-old in the United States is 12.5 years, and low-risk patients have an average time to progression to AML of 9.4 years (Greenberg et al., 1997). A diagnosis at older age does not indicate a death sentence. With proper treatment, an older adult can live an active life despite myelodysplastic diseases.

Family caregivers have an important role in ongoing care. Kurtin likes to call them her “truth squad” because family members and friends often can see things that the patient does not realize are occurring regarding the patient’s health, such as cognitive problems and mood or personality changes. In addition, some patients may not want to admit certain symptoms for many reasons, including fear of disease progression or not wanting to be a burden. Family caregivers, including significant others, children, siblings, and friends, can provide an accurate assessment of daily life that clinicians are unable to observe in the brief window of an office visit (see Figure 1).

Family can observe indicators of wellness, such as appetite, activity level, weakness, lack of endurances, shortness of breath, and sleeping habits (Pal et al., 2010). These indicators are important for identifying prognostic factors not included in standard

**Physical**

Decreased strength, decreased body organ function, altered immune response, diminished physiologic reserve, increased risk of developing concurrent illness, asthenia, exacerbation of other health conditions (e.g., CHF), dyspnea, bone pain and discomfort, malaise, fever, bleeding, weight loss, skin rash, symptoms from therapy, night sweats, and limited ability to adequately treat other conditions (e.g., hip replacement)

**Social**

Altered role function, diminished social interaction with friends and family, diminished economic resources, diminished social network, increased financial burden from health care, time associated with therapy, activity restrictions, planning for future, transportation challenges, altered support from family and friends, economic challenges, and alteration in sexuality

**Emotional**

Anxiety, loneliness, despair, uncertainty, anger and frustration, depression, communication with the healthcare team, and patient-provider relationship

**Functional**

Fatigue, potential for decreased cognitive function, diminished stamina, decreased mobility, missed work associated with illness and therapy, diminished ability to perform IADLs or ADLs, diminished independence, cognitive dysfunction, and demands of illness

**Spiritual**

Renewed appreciation for life, renewed appreciation for relationships, enhanced faith and beliefs, hopelessness, abandonment, loss of self, and search for balance (e.g., positive and negative aspects of life)

ADL—activities of daily living; CHF—congestive heart failure; IADL—instrumental ADL


**Figure 1. Quality-of-Life Issues by Domain for Patients With Myelodysplastic Syndromes**

functional status, and determining frailty.

**Treatment Options**

Unlike other cancers, such as lymphoma, where clinicians have a multitude of agents in their arsenal, Kurtin likened the treatments for myelodysplastic disorders as a tasting menu rather than an extensive buffet. Although research for novel therapies is ongoing, currently only three agents are approved by the U.S. Food and Drug Administration for treatment of myelodysplastic disorders: azacitidine, lenalidomide, and decitabine (Kurtin & Demakos, 2010). Therefore, clinicians need to adequately pace themselves so they do not run out of treatment options.

Although allogeneic stem cell transplantation offers hope for a cure, this is not an option for most patients, and not every patient who undergoes transplantation will experience a complete response (Kurtin, 2011; Kurtin & Demakos, 2010). However, stem cell transplantation does offer the benefits of stabilizing disease, improving hematologic status, and minimizing the need for transfusions.

In regard to treating older adults with myelodysplastic syndromes, treatment usually aligns with the National Comprehensive Cancer Network’s approach to oncology care. This guideline provides a range of characteristics that encompass older adults who are functionally independent and are candidates for most treatment options to those with poor prognosis and functional status where the focus of treatment is supportive care and symptom management (National Comprehensive Cancer Network, 2011, 2012). However, one formula does not apply to all patients with myelodysplastic diseases, and treatment plans can change throughout the disease trajectory. Kurtin noted that treatment triggers can alert clinicians as to the need to modify therapy. These triggers include when a patient becomes dependent on transfusions, progression or increased symptom burden of cytopenias, increased blasts, and progression to high-risk disease.

**Patient and Caregiver Education**

Sara M. Tinsley, ARNP, AOCN®, expressed the importance of clear communication and patient and family education when treating myelodysplastic syndromes. “Patients really want clear information about what their diagnosis is. It’s not like when patients with breast cancer tell their friends, and everyone knows what they have, so they don’t have to go into a lot of explanation. Patients with myelodysplastic syndromes have the task of explaining what their disorder is, not only to their friends and family, but also to other healthcare providers who may not care for many patients with these syndromes.”

Jayshree Shah, APN-C, AOCN®, MSN, BSN, BS, RN, CCRP, indicated that nurses are in a position to empower patients and families to be active participants in their care. Oncology nurses can directly affect outcomes by thoroughly understanding the disease state and available treatment options, educating patients and families in plain language about elements of treatment such as duration of therapy and potential adverse events, and providing strategies for how the patients can positively affect outcomes through healthy lifestyle choices (Kurtin, 2012). Shah also reminds nurses that a multidisciplinary approach to care using effective communication strategies among all healthcare professionals (e.g., specialists, primary care physicians, pharmacists, other nurses) results in better patient outcomes (Kurtin, 2012).

Healthcare professionals also can help by considering lifestyle factors, such as older adults who are able to drive but need to schedule appointments in the daytime because they have poor night vision. Although some older adults are retired, many still may need to schedule treatments around work schedules or social commitments. Offering this flexibility will not only allow patients to maintain active lifestyles but also will help motivate them to stick with the treatment schedule.

Kurtin said that it is important for patients and families to understand that, unlike many cancers that have a definitive beginning and end to treatment, myelodysplastic syndromes are chronic illnesses that require management for the remainder of the patient’s life span. Patients may express frustration with this, and nurses should frequently remind them that treatment is “a marathon, not a sprint.”

Although life-sustaining, treatment for myelodysplastic syndromes is difficult and time intensive. Patients can be subjected to many transfusions over the course of their lifetime. “Unfortunately, cytopenias are expected to become worse before they get better because treatment cleans the marrow to allow for the new growth of healthy cells,” Kurtin explained. Worsening cytopenias will naturally lead to a more intense symptom experience. In addition, treatments also will suppress patients’ immune systems, thus requiring them to take extra precautions to avoid infections. Kurtin stressed that patients and families need to thoroughly understand this trajectory at the outset of treatment so that they avoid frustration and discouragement. Patients who understand the disease process and that they need to “get to the other side of the [cytopenias] ravine” before their condition can improve are more likely to comply with the treatment regimen.

In addition to the effects of immuno-suppressive therapies and worsening cytopenias, patients also will have to deal with toxicities related to multiple transfusions. Shah noted that healthcare professionals should be aware of the potential for iron overload because each unit of packed red blood cells that a patient receives contains 25 mg of inextricable iron. This extra iron cumulates in the heart, liver, and endocrine system, which can lead to toxicities in these organs. Iron chelation therapy can correct this, but Shah warns that this is not without side effects. Patients who undergo chelation therapy can experience pancytopenia, high-frequency hearing loss, and ocular disorders, such as...
cataracts and increased pressure (Jabbour, Garcia-Manero, Taher, & Kantarjian, 2009; Kurtin, 2007; Malcovati et al., 2005).

**Reliable Resources for Patients**

Shah noted that the International Nursing Leadership Board of the Myelodysplastic Syndromes Foundation has created a patient education tool called *Building Blocks of Hope: A Patient and Care Giver Guide for LIVING With MDS*. The guide answers questions about the syndromes and their treatment options, and offers suggestions about how patients can adopt healthy strategies and be an active part of the treatment team. The guide encourages patients to continue with usual activities while using common sense to avoid illnesses associated with suppressed immunity.

Tinsley suggested that, in addition to information nurses can provide during appointments, a wealth of resources are available on the Internet from many organizations, such as the Myelodysplastic Syndromes Foundation (www.mds-foundation.org), the Leukemia and Lymphoma Society (www.lls.org), and the American Cancer Society (www.cancer.org). These sites offer patient-specific information written in clear language that helps to cut through medical jargon. Some sites offer access to support groups, message boards, and clinical trial information.

**Summary**

To effectively manage myelodysplastic syndromes, clinicians must have a thorough grasp of the disease state, treatment trajectory, and expected side effects. In addition, effective communication, both through patient education and among multidisciplinary team members, will help improve treatment compliance and patient outcomes.

Kurtin stressed that continued treatment provides the best opportunity for positive responses. She noted that barriers to treatment, including clinicians’ ageism toward patients, patients’ and caregivers’ perceptions of lack of treatment benefit, treatment noncompliance, and toxicities and adverse events, can be overcome by clear expectations and care plans, rapid identification and management of side effects and adverse events, and a partnership with the patient and family (Eliasson, Clifford, Barber, & Marin, 2011). Overcoming these barriers can help to ensure that patients with myelodysplastic syndromes can live full, active lives despite their illness.

—Reporting by Laura J. Pinchot, BA

**References**


**JUST BACK:**

**AARP National Event in New Orleans**

A special thank you to Joan Weidenfeld, a member of our MDSF Development Committee, for suggesting that we attend the AARP Convention to spread MDS awareness. Our booth was well attended and we were able to distribute a great amount of information. It was the first time that we had an MDS patient joining us at our exhibit booth. We look forward to another successful event next year.

*Her idea made a difference!*

---

**COMING SOON**

**Building Blocks of Hope™**

A global MDS Foundation print and online patient advocacy initiative, providing a personalized educational program for the patient and caregiver to prepare, participate, and **LIVE** with MDS.

---

**Dec. 8-11**

**Visit us at ASH**

**booth# 3505**

---

The 12th International Symposium on Myelodysplastic Syndromes

**Preliminary Timetable** *subject to change*

<table>
<thead>
<tr>
<th>Plenary Session</th>
<th>Interactive Session</th>
<th>Poster Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>Social Event</td>
<td>Oral Session</td>
<td>Best Abstracts</td>
</tr>
</tbody>
</table>

**Wednesday, May 8, 2013**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00-17:00</td>
<td>Morphology in MDS (Microscopy, basic-course, advanced course)</td>
</tr>
<tr>
<td>17:00</td>
<td>Opening Ceremony</td>
</tr>
<tr>
<td>19:00</td>
<td>Welcome Reception</td>
</tr>
</tbody>
</table>

**Thursday, May 9, 2013**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30-10:00</td>
<td>Plenary I: PathogenOMEs in MDS – new players and well known gamblers</td>
</tr>
<tr>
<td></td>
<td>1. The Genome</td>
</tr>
<tr>
<td></td>
<td>2. The Spliceosome</td>
</tr>
<tr>
<td></td>
<td>3. The Epigenome</td>
</tr>
<tr>
<td></td>
<td>4. Impact of alterations of OMEs for Classification: IWG-PM/Molecular</td>
</tr>
<tr>
<td>10:00-10:30</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>10:30-11:30</td>
<td>Plenary II: Diagnosis in 2013 – state-of-the-art</td>
</tr>
<tr>
<td></td>
<td>1. WHO 2013</td>
</tr>
<tr>
<td></td>
<td>2. Cytogenetic Advances</td>
</tr>
<tr>
<td></td>
<td>3. IPSS-R(revised)</td>
</tr>
<tr>
<td>11:30-12:30</td>
<td>Interactive I: Challenging diagnostic cases – does molecular genetics lead the way?</td>
</tr>
<tr>
<td></td>
<td>1. RA/RCMD – RAEB-I – RAEB-II - AML</td>
</tr>
<tr>
<td></td>
<td>2. CMML</td>
</tr>
<tr>
<td></td>
<td>3. RARS-T</td>
</tr>
<tr>
<td>12:30-13:30</td>
<td>Lunch</td>
</tr>
<tr>
<td>13:30-14:30</td>
<td>Plenary III: What can MDS-specialists learn from …</td>
</tr>
<tr>
<td></td>
<td>1. Childhood MDS</td>
</tr>
<tr>
<td></td>
<td>2. Progeria</td>
</tr>
<tr>
<td></td>
<td>3. Overlap of BMF and MDS</td>
</tr>
<tr>
<td>14:30-16:00</td>
<td>Oral Session I – Pathogenesis</td>
</tr>
<tr>
<td>16:00-16:30</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>16:30-18:00</td>
<td>Poster Session (+ guided poster discussion)</td>
</tr>
</tbody>
</table>

Visit Berlin, network with colleagues, meet the experts, learn and present your own research. Join us at the MDS 2013 Symposium.
### FRIDAY, MAY 10, 2013

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30-10:00</td>
<td>Plenary IV: Treatment of low risk MDS patients – the standard, the new</td>
</tr>
<tr>
<td></td>
<td>1. Immunosuppressive therapy</td>
</tr>
<tr>
<td></td>
<td>2. Iron chelation – initiation based on LIC rather than serum ferritin?</td>
</tr>
<tr>
<td></td>
<td>3. ESA/TSAs – The higher the dose, the better the response?</td>
</tr>
<tr>
<td></td>
<td>4. Lenalidomide as a standard treatment for low risk MDS with 5q abnormality?</td>
</tr>
<tr>
<td>10:00-10:30</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>10:30-11:30</td>
<td>Plenary V: Treatment of high risk MDS patients</td>
</tr>
<tr>
<td></td>
<td>1. Molecular targets – treatment options</td>
</tr>
<tr>
<td></td>
<td>2. Hypomethylating agents for treatment of high risk MDS</td>
</tr>
<tr>
<td></td>
<td>3. Combination regimens in high risk MDS</td>
</tr>
<tr>
<td>11:30-12:30</td>
<td>Interactive II (allo SCT)</td>
</tr>
<tr>
<td></td>
<td>1. Patients selection</td>
</tr>
<tr>
<td></td>
<td>2. Pre treatment</td>
</tr>
<tr>
<td></td>
<td>3. Management of graft versus host disease</td>
</tr>
<tr>
<td>12:30-13:30</td>
<td>Lunch</td>
</tr>
<tr>
<td>13:30-14:30</td>
<td>Best abstracts (Bastianello Awards)</td>
</tr>
<tr>
<td>14:30-15:00</td>
<td>Oral Session II – treatment and trials</td>
</tr>
<tr>
<td>16:00-16:30</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>16:30-18:00</td>
<td>Poster Session (+ guided poster discussion)</td>
</tr>
</tbody>
</table>

### SATURDAY, MAY 11, 2013

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30-10:00</td>
<td>Oral Session III – prognostication and CoL</td>
</tr>
<tr>
<td>10:00-10:30</td>
<td>Coffee break</td>
</tr>
<tr>
<td>10:30-12:00</td>
<td>Plenary VI: Future perspectives and new drug development</td>
</tr>
<tr>
<td></td>
<td>1. Microenvironment</td>
</tr>
<tr>
<td></td>
<td>2. Next generation sequencing – diagnostic/prognostic key?</td>
</tr>
<tr>
<td></td>
<td>3. Therapy related MDS</td>
</tr>
<tr>
<td></td>
<td>4. Pipeline overview: Disease modifying drugs in MDS</td>
</tr>
<tr>
<td>12:00-12:30</td>
<td>Closing Remarks</td>
</tr>
</tbody>
</table>

Symposium Chairmen:
Arnold Ganser, M.D., Ph.D.  
Hannover Medical School, Germany  
Wolf-Karsten Hofmann, M.D., Ph.D.  
University Hospital Mannheim, Germany

www.kenes.com/mds
MDS Resources

Highlights of Latest Literature in MDS

Suneel D. Mundle, PhD

Listed below are citations of some new publications relevant to MDS (pathogenesis, clinical characterization, management, etc.). To access the complete article log on to www.pubmed.gov.

EPIDEMIOLOGY:

   The report presented analysis of 58,800 cases incidence between 1995-2002 from 48 population-based cancer registries in 20 European countries. Among myeloid malignancies, the five-year overall survival estimates were 17% for AML, 20% for MDS/MPD neoplasms, 31% MDS and 63% MPD.

   A retrospective chart review of MDS patients (N=252) seen between 2000–2010 at a single random genetic event that causes a multi-event process.

   The article describes a flow chart for a primary care physician with different indicators of the need for differential diagnosis of MDS. This flow chart suggests immediate referral to specialty physician if bi- or multi-lineage cytopenias are seen. For a mono-lineage cytopenia the referral is advised after ruling out the common causes of cytopenia.

   The authors have identified a communication gap between MDS treaters, patients and their caregiver and have provided listing of valuable knowledge resources to assist in bridging the gap.

   A 5-year home care program evaluating 211 patients treated during its implementation has underscored the feasibility of at-home transfusions preserving the quality of life. The report however, warrants regarding the provision of a dedicated home care service for this purpose.

DIAGNOSIS/PROGNOSIS:

   Combining MDS patient databases from several international institutions offered a pool of 7012 MDS patients in the revised analysis (IPSS-R) compared to 816 patients included in IPSS. Cytopenias, cytogenetics and marrow blast counts remained foundational in IPSS-R, albeit with more detailed categorization and addition of several new entities. The new model recommends five prognostic categories as opposed to the original four. The new categories are very low, low, intermediate, high and very high risk with overall survival of 8.8, 5.3, 3, 1.6 and 0.8 years respectively.

   By using a model to estimate the risk of leukemic transformation as a function of time from the diagnosis in 1079 patient records from Düsseldorf MDS registry, the authors have demonstrated the risk of transformation remained constant especially in low, int-1 and int-2 IPSS categories. As a result the report concluded that there may be a single random genetic event that causes a leukemic transformation as opposed to a multi-event process.

   A multi-national working group tasked in 2008 to propose standards for flow cytometry has refined the minimum criteria to assess dysplasia by flow cytometry to potentially categorize subjects as normal, or suggestive of MDS or diagnosed of MDS. The working group has suggested that flow cytometry should be a part of the integrated diagnostic panel for MDS rather than being a standalone technique.

   The median survival for the entire group was 74 months (44 months in transfusion dependent vs. 97 months in transfusion-independent, p<0.0001). Of the total of 381, 48% progressed to AML with a calculated risk of transformation being 4.9% at 2 years and 17.6% at 5 years. The associated prognostic factors were transfusion dependency, >5% marrow blasts and high WPSS score.

TREATMENT:

Hematopoietic Cell Transplantation (HCT):

   Treatment-related mortality and relapse have continually posed barrier to the success of HCT therapy. To this end, with the availability of cord blood stem cells and success with HLA-haploidentical donors, authors suggested a possibility of offering HCT to all patients and expressed optimism for cure in 25–75% based on the disease burden with 70% experiencing good to excellent quality of life.

   A retrospective review of 68 cases of MDS or MDS AML with high-dose (40%) or reduced dose (60%) azacitidine in 35 patients and induction chemotherapy in 33 patients prior to HCT, showed 1 year post transplant survival of 57% with azacitidine vs. 36% with induction chemotherapy. The risk of post-HCT mortality, non-relapse mortality and relapse rates were lower with azacitidine.

Hematopoietic Growth Factors:

   Previously authors reported 60% erythroid response rate with the above combination in...
63 elderly patients with clinical features otherwise unfavorable to erythroid response. The present update with a 7-year follow up showed that especially in non-RAEB patients, median duration of response was 22 months, overall survival was 55 months and among the erythroid responder subset the survival at 3-year from diagnosis was 90%.

**Iron Chelation:**

   A comparison of two groups of 94 MDS patients each with or without iron chelation treatment for transfusion related iron overload demonstrated a significant overall survival difference in favor of chelation (74 months in treated vs. 49 months untreated patients, p=0.002).


   A three year prospective multicenter trial treated 173 patients with iron overload (serum ferritin ≥1000 g/L and had received ≥20 RBC transfusions with a continued requirement) with deferasirox (20 mg/kg/day—escalation allowed to 40 mg/kg/day). Mean serum ferritin decreased with a 23%, 36.7% and 36.5% among those treated for a length of 1 year, 2 year or 3 year respectively. In addition, in all patients with abnormal baseline labile plasma iron, normalization was seen by week 13. Overall, 28% patients showed hematologic improvement (HI) response. The common drug-related adverse events included gastro-intestinal disturbances and elevated serum creatinine.


   A post-hoc analysis of the EPIC study in an eligible subset of patients without any concomitant medications demonstrated hematologic improvement; 21.5% erythroid response, 13% platelet response, and 22% neutrophil response after 109, 169 and 226 days of treatment with deferasirox respectively. Labile plasma iron reduction ≤0.4 M/L was observed starting from week 12.

**IMiDs:**

   Low/int-1 patients failing prior EPO were treated with 10 or 15 mg/day lenalidomide first (N=39). At week 16 non-erythroid responders were initiated on additional treatment with 40,000 IU/week rhu-EPO. With lenalidomide monotherapy, erythroid response (HI-E) was higher in del 5q patients (86%) than the others (25%). Among 23 non-responders to monotherapy and receiving combined treatment the eventual HI-E rate was 26%. The combination is being studied further in a phase III study by ECOG.


   A combination of azacitidine (75 mg/m²/day x 5 day) and lenalidomide (10 mg/day x 21 days) in a 28 day cycle was administered to a group of int-1/int-2 and high-risk MDS patients (N=36). The most common grade 3/4 adverse event was febrile neutropenia (22%). Overall response rate was 72% (CR-44%, HI-28%). Median CR duration was 17+ months and median overall survival for all patients was 13.6 months.

**Demethylating Agents:**

   A model comparing 6556 MDS patients diagnosed between 2001–2007 (≥66.5 years) and taking into account MDS survival probability, estimated MDS-related-5 year cost to be higher than 18 most prevalent cancers in the USA. Furthermore for MDS, when a time period prior to the availability of hypomethylating agents (Jan 2001–Jun 2004) was compared to period after their availability (Jul 2004–Dec 2007), in parallel with an improvement in 24-month survival, the cost of patient management for 24 months was also found to be increased ($97,977 after, 2004–2207, vs. $42,628 before, 2001–2004, the availability of hypomethylating agents).


   Development of thrombocytopenia is common with hypomethylating agents. The present study tested romiplostim (n=15) vs. placebo (n=14) given concomitantly with decitabine. Mean platelet counts at the beginning of each new cycle of decitabine were higher. Also, the bleeding events and platelet transfusion rates were notably lower in romiplostim treated patients. The overall therapeutic response too was better with simultaneous administration of romiplostim.

**Other Agents:**

   SCIO-469 was tested at four total oral daily dose levels 90, 180,270,360 mg/day in low/int-1 MDS patients who previously did not respond to EPO (N=62). Hematologic improvement was seen in 29% patients with a median time to respond as 72 days and duration of response ranging from 63 days to >2 years. One patient each had complete or partial response and 58% patients had stable disease. Approximately 18% (11 patients) discontinued treatment due to adverse events.


   Forty three higher-risk MDS patients received bortezomib (1.5 mg/m² on days 1,4,8,11) and low dose cytarabine arabinoside (10 mg/m², then 20 mg/m² on days 1–14) every 28 days for four cycles. With a median 29.7 months follow up, overall 28% response was seen including 1 CR. Response seemed to be limited to previously untreated patients and the responders had a superior overall survival (18.2 months) as compared to the non-responders (10 months). Major side-effects included hematologic toxicities and neuropathy.


   In a preclinical part of the study, ON01910.Na suppressed cyclin D1 expression in MDS patients’ bone marrow mononuclear cells. Additionally in the Phase I clinical study with 12 higher risk MDS and 8 AMLs with trisomy 8, three patients showed ≥50% decrease in marrow blast counts (15%) and 3 had hematologic improvement (15%). The latter
responders showed drop in cyclin D1 expression in their marrow CD34+ cells.

**PATHOBIOLOGY:**

A methylation-specific PCR in 126 de novo MDS patients demonstrated p73 gene methylation in the bone marrow mononuclear cells of 36.5% patients, which correlated with blast count and WHO classification. In vitro, decitabine restored p73 expression via its demethylation activity and increased Ara-C induced apoptosis of the bone marrow cells. The median survival was shorter in patients with methylated p73 gene as compared to those without methylation (15 vs. >33 months respectively, p=0.002).


MDS News Briefs

**Launch of Fast Track for First Prescription Service through Celgene Patient Support**

Fast Track for First Prescription™ is a new opt-in service from Celgene Patient Support® which helps patients on an oral Celgene product receive their first prescription faster.

**Which patients are eligible for this program?**

- Patients on an oral Celgene product receiving their first prescription
- Patients with documented proof of insurance
- Patients who are registered in a Celgene risk management (REMS) program and have a valid authorization number

**How are eligible patients enrolled in this program?**

- Prescriber must fax the Fast Track Cover Sheet and the Patient Prescription Form with the authorization number and the patient risk category (i.e., adult female of childbearing potential, adult male, etc) to 1-800-822-2496
- Patient’s contact information and insurance
- Prescriber must ensure patient has completed their Celgene risk management (REMS) survey

**What can a patient expect after being enrolled in this program?**

The specialty pharmacy will contact the patient to:

- Review their insurance benefits for the prescribed product (i.e., co-pay responsibilities and potential financial co-pay assistance options)
- Provide appropriate counseling (if applicable)
- Set up a delivery date for shipment of the medication

For more information, or for any questions, call Celgene Patient Support® at 1-800-931-8691.

**REVIEWS AND PERSPECTIVES:**

The following articles provide significant review of literature and/or innovative perspective on the state-of-the-art in MDS and identify need for additional prospective studies.


We would like to thank Suneel Mundle, a member of the MDS Foundation, for his assistance in monitoring these important peer-review publications on MDS.

**New Published MDS Supplement in the American Journal of Medicine**

View the recently published, supplement on MDS in the American Journal of Medicine. These articles are available on the internet through open access, allowing interested parties to download the entire supplement for free.

http://www.amjmed.com/supplements

**New Website Resource for Iron Overload Management**

Iron Health Alliance is a new global initiative dedicated to increasing awareness and sharing up-to-date information about iron toxicity with physicians and patients around the world.

http://www.ironhealthalliance.com/index.jsp
What is MDS?

Myelodysplastic Syndromes (MDS) are a group of diverse bone marrow disorders in which the bone marrow does not produce enough healthy blood cells. MDS is often referred to as a “bone marrow failure disorder”. MDS is primarily a disease of the elderly (most patients are older than age 65), but MDS can affect younger patients as well. To help you better understand MDS, it might be helpful to first consider some basics about bone marrow and blood. The bone marrow functions as a factory that manufactures three kinds of blood cells: red blood cells, white blood cells, and platelets. Healthy bone marrow produces immature blood cells—called stem cells, progenitor cells, or blasts—that normally develop into mature, fully functional red blood cells, white blood cells, and platelets. In MDS, these stem cells may not mature and may accumulate in the bone marrow or they may have a shortened life span, resulting in fewer than normal mature blood cells in the circulation. Many patients have no noticeable symptoms of MDS and are diagnosed on routine screening. Others present with vague symptoms such as fatigue, shortness of breath, palpitations, fever, recurrent or prolonged infections, bruising, petechiae, or bleeding.

About Us

The MDS Foundation, Inc. is a multi-disciplinary, international organization devoted to support, research, treatment, and education for patients, caregivers, physicians, nurses and other health care providers. The organization is based upon the premise that international cooperation will accelerate the process leading to the control and cure of these diseases.

MDS Foundation Publications

The MDS Foundation provides referrals to our Centers of Excellence and the following information to physicians and patients, free of charge:

- The MDS News
- The MDS Messenger (Free E-News)
- Patient Diary
- What Does My Bone Marrow Do?
- Understanding Myelodysplastic Syndromes: A Patient Handbook*
- Insurance and Reimbursement Resources for MDS Patients

Foundation Initiatives

- Worldwide Patient Quality-of-Life Forums
- Worldwide Patient Support Groups
- International Nurse Leadership Board
- Professional Education

Contact Us

Please contact the MDS Foundation for additional information.
E-mail: patientliaison@mds-foundation.org

*The MDS Patient Handbooks are available in English and the following languages:

VISIT OUR WEBSITE TO JOIN AS A MEMBER OF THE FOUNDATION AND TO LINK TO OUR EDUCATIONAL RESOURCE CENTER:

www.mds-foundation.org

MDS Foundation, Inc., 4573 South Broad Street, Suite 150, Yardville, NJ 08620
Within the US: 1-800-MDS-0839, Outside the US: 609-298-1035
Worldwide Patient Forums and Support Groups

NOW FORMING: MDS PATIENT AND FAMILY SUPPORT GROUPS

Whether you are interested in starting a much needed support group in your area or looking to join one, please contact the MDS Foundation at: 800-MDS(637)-0839 or email ahassan@mds-foundation.org.

The MDS Foundation has developed a strategy for setting up patient groups and assistance is now available to organize support groups for MDS patients. Any member of the Foundation, patients, friends, family members, and caregivers are invited to join with us to move this project forward.

PLEASE MAKE SURE TO REGULARLY CHECK OUR ONLINE UPCOMING EVENTS CALENDAR FOR MEETINGS TAKING PLACE IN A CITY NEAR YOU!

Lakeland Patient Support Group
Lakeland, Florida

“It was a great opportunity for each person to express their expectations for the group, not just for now, but for the future. As this cancer is rare, many patients feel isolated and singular. Our goals for the group are to encourage and support one another and to gain more knowledge about this rare disease. Everyone felt that the above goals were accomplished and are looking forward to meeting again!”

Katherine Dempster

(L to R) Linda and Richard Brackett, Bonnie and Arnold Henig, Don and Katherine Dempster, Dave Paul. Vivian Paul, photographer

Our goals for the group are to encourage and support one another and to gain more knowledge...

The Lakeland Regional MDS Support Group was held at the home of Dave and Vivian Paul in Lakeland, Florida. For more information, contact the Dempsters at (863) 816-8482 or the Pauls at (863) 698-5137.

Southern California MDS Patient Support Group

“People started talking, asking questions and before we knew it 2 hours had gone by. It seemed like everyone that had questions got the answers that they were looking for.”

Susan Urban

The Southern California MDS Support Group meets every third Saturday of the month at St. Mary Star of the Sea Church, 609 Pier View Way in Oceanside, California at 2:30 PM. For more information, contact Susan Urban at (760) 966-0895 or susanurb@gmail.com. Access the following link to view their website: http://robnixonii.wix.com/socalmdssupport#!home/mainPage
Toronto, Canada MDS Patient Support Group

"...we had 41 attendees (much larger than we had expected)... Dr. Karen Yee did a presentation for the first hour. She presented a general overview of MDS and then spent a lot of time talking about the different treatment options with a great overview of current clinical trials. Participants had an opportunity to ask questions. In the second hour, David Walkup facilitated a support/educational session using an MDS tool that his company (Healthy Interactions) has developed with some health care providers and a patient. It was a very powerful, engaging session. He was asking for participants’ feedback prior to finalizing the tool.”

Cindy Murray
Nurse Group Leader
Princess Margaret Hospital

Patient and Family Education Forums
FREE One-Day Conferences for MDS Patients and their Families

Thank you to all who have attended our MDS Patient and Family Conferences in 2012. Ongoing meetings addressing quality of life issues for MDS patients will be planned and these conferences will occur in ten cities around the world in 2013. A global patient forum will be held alongside our 12th International Symposium on MDS in Berlin, Germany. Check our website and facebook for updates. We look forward to another successful year!

Request Your FREE Patient Information Packet Today

The MDS Foundation has many resources on MDS-related topics, straight from leading experts in the field of MDS. Request your FREE patient information packet from the MDSF, containing up to date education on MDS in patient-friendly language. Many are also available in other languages. Order your patient packet today by calling 800-MDS-0839 or email jbutchko@mds-foundation.org.
Hamilton, Ontario MDS Patient Support Group

“Our attendance was the best ever, 40 people. My MDS hand outs were well received. The excitement surrounding our webpage was unbelievable. Dr. Leber hopes we can get it up and running before year end. He also wants to know if videos can be attached. People were in awe about the webpage.”

William Pearson
Hamilton, Ontario MDS Patient Support Group

The Hamilton, Ontario group meets at the Emmanuel United Church, 871 Upper Ottawa Street, Hamilton 10:00 am to 12:00 noon. For more information, contact Tammy DeGelder, RN at (905) 521-2100, ext. 73435 or William Pearson (905) 561.6999 or e-mail to: william.pearson@sympatico.ca.

SPREADING THE NEWS WORLDWIDE

NEW YORK CITY
MDS PATIENT SUPPORT GROUP
– Now Being Formed –

Would you like to join an MDS Support Group in New York City?

Meet others with similar challenges, share hopes, and frustrations, gather information to better understand MDS, listen to healthcare professional presentations, and socialize!

Contact ahassan@mds-foundation.org for more information.
NEW ITEM ADDED – MDS SILICONE BRACELETS

Help Spread Awareness of MDS and Order Your Silicone Bracelets Today!

For a donation of your choice, receive your custom silicone bracelet(s) as a “Thank You” for your generosity. To order, call 800-MDS(637)-0839 or order by mail with check enclosed to:

The MDS Foundation, Inc.
4573 South Broad Street
Suite 150
Yardville, NJ 08620

Thank you for your support!
When the Doctor Tells Your Wife, “You Have Blood Cancer”

John Bugay

When your doctor tells you, “you have blood cancer,” it’s certainly one of the major challenges in life. I was with my wife Bethany when she heard those words.

She is a fighter, and thanks to a bone marrow transplant at Pittsburgh’s West Penn Hospital, most of the fight is behind us. But I wanted to share, from a family member’s point of view, what’s involved with those challenges.

The Road to Leukemia

On an early summer day last year, Beth had to call off work because she was simply too tired to get out of bed. That wasn’t like her at all. A veteran of the Iraq war, who got there just a month after the lead invasion in 2003, she was not a person to back down from any challenge.

For a little over a year, I’d been working days, and she had been working full-time nights. Our youngest daughter was in school, and this work schedule enabled us to avoid daycare expenses. Plus, we needed two incomes to make up for the eight months I had been unemployed during the recession.

But over the previous several months, Beth had been coming home more tired than usual, and complaining of headaches. On this Sunday morning, she came home and went right to bed. That afternoon, she had to call off work, something she never did. She couldn’t get out of bed. She had a headache, body aches, swelling of the legs. Her supervisor said, “why don’t you go to MedExpress and get yourself checked?” So we did.

The practitioner on duty that night examined her, came back in and said, “You need to have some tests tonight that I can’t give you. I’m going to send you up to the emergency room”.

The practitioner on duty that night examined her, came back in and said, “You need to have some tests tonight that I can’t give you. I’m going to send you up to the emergency room”. They gave her some blood transfusions and admitted her for more tests. One of the nurses told us that if she had cut herself and bled out to that level, she’d be unconscious. But because she dropped slowly to that level, her body gradually adapted to it.

Challenge 1: The Diagnosis Takes Time

At the hospital, there were a number of tests, one of which was a bone marrow biopsy. After all the tests that had been done and the bone marrow biopsy was headed for the lab, her hematology/oncology physician said he thought that it was most likely a viral infection causing her severe anemia.

A follow-up visit to our GP came back with the news: “you have a form of blood cancer”. It was awkward for him and an incredible shock to us. He gave us a copy of the lab results, which said “Acute Myeloid Leukemia (AML) is indicated.”

Her immediate thoughts turned to questions such as, “what’s going to happen to me physically?” And the spiritual questions came up, “Am I prepared to die?” “Am I right with God?” As a family member, I was certainly concerned with her spiritual well-being. But in addition, we have six children, some of them young, and it was important to me to understand how to move forward through these challenges.

One of the hardest things about hearing the diagnosis “you have a blood cancer” is simply putting it into perspective. I spent some time Googling “AML”, and found some excellent information, but it was certainly discouraging for us, because, as it turned out, I wasn’t looking in the right ballpark.

But at that point, we didn’t even have a good understanding of the diagnosis.

Challenge 2: Understanding MDS and Leukemia

A few days later, a brief talk with our hem/onc physician helped us to better understand where Beth’s diagnosis fit within the world of leukemia. Science has greatly enhanced the medical field’s understanding of the disease and its many different variations, especially from a genetic standpoint, but that doesn’t make it any easier for the patient to understand what’s going on.

Nevertheless, it was a conversation that enabled me to narrow the focus of my searches.

There are four types of “blood cancers”: chronic and acute myeloid leukemia, and chronic and acute lymphoma. Of course, these are just terms that set the four types in contrast with each other, for the purpose of categorization; there are really a number of different subvariations in each of these categories, each with a broad range of things that can go wrong.

The particular group of leukemias that Beth had, AML, is a very nasty one. The preliminary diagnosis turned out to have been for a “pre-leukemia” version, one of the “myelodysplastic syndromes” (MDS).

We were scheduled to see yet another specialist, Dr. James Rossetti from West Penn Hospital in Pittsburgh.
He told us that the diagnosis was pretty clear about “what” it was but somewhat inconclusive on the severity continuum. There is a “risk factor” chart called the IPSS chart, and Beth was either at a “high” risk level (the highest of the four) for developing AML, or she actually had moved into AML. Dr. Rossetti did another bone marrow biopsy, and admitted her to the hospital for further testing.

What came back was something called CMML, or chronic myelomonocytic leukemia, a sort of hybrid kind of disease, between MDS and a “myeloproliferative” variation of the disease. More specifically, Beth was found to have “dysplastic CMML-2”, which is not as bad as having the “myeloproliferative” version of CMML, but it is not a good thing.

Untreated, the prognosis for CMML was a lifespan of about 12–24 months. Dr. Rossetti was very clear that because of her age (50) and relative good health, she was a prime candidate for what they called a “bone marrow transplant” (BMT).

That in itself opened up a whole new world to have to understand. As it turned out, the hardest part was yet to come.

**Challenge 3: The Treatment**

After learning about the diagnosis, we finally got a complete overview of the treatment plan:

1. Two or three courses of Vidaza to try to slow or mitigate the effects of the disease. It was key to prevent the CMML from developing into AML.
2. A search for a donor.
3. Upon finding a donor, a period of “conditioning,” intense chemo and full-body radiation, essentially to destroy her existing, damaged bone marrow.
4. The transplant itself, an infusion of adult stem cells from an anonymous donor.
5. Follow-up to check on the effects of the transplant.

The expectation was that the Vidaza would reduce her overall “risk level” (that her disease would progress into full-blown AML) and strengthen her body for “conditioning”, which would kill most if not all of the cancer-causing function in her bone marrow.

The “transplant” would do two things. First, the new stem cells would take up residence in her bones and repopulate her now-destroyed bone marrow. Second, the differences in the DNA match would provide a “the graft-vs.-tumor effect” to suppress and kill any latent cancer function within her body.

Prior to the transplant, Beth’s possible outcomes were:
- 30% cure;
- 20% immediate complications;
- 15% major longer-term complications;
- 35% chance of relapse.

**Challenge 4: The Transplant Itself**

Beth actually ended up having six courses of Vidaza, which had the intended effect of controlling the spread of the disease and actually reducing the cellularity in her bone marrow (from 50% down to about 20%), partially doing the job of the “conditioning” step.

By November 9th a donor had been selected, and on December 14, 2011, the stem cells from our adult female donor were flown into Pittsburgh on an international flight. Beth received her transplant from approximately 9:45 pm until around 10:35.

This was “Day Zero” of her new life. And while the transplant itself may have been uneventful, as it turned out, there was a MRSA infection on her central line (used to input the stem cells). So the night of the transplant and for several days following, Beth experienced some of those “immediate complications”: a fever as high as 103°F, violent chills and shakes.

At one point, she said, “It hurts Johnny”. “What?” I said. “Everything,” she said.

She was very frightened by the reaction. They treated her with a number of fever medications as well as ice packs. Meanwhile, I had taken off a great deal of time from work to spend time with her in the hospital. During that time, I had to run back and forth between home, to check on the kids, and hospital, to be with Beth.

The “transplant” would do two things. First, the new stem cells would take up residence in her bones and repopulate her now-destroyed bone marrow. Second, the differences in the DNA match would provide a “the graft-vs.-tumor effect” to suppress and kill any latent cancer function within her body.

In all, she spent the better part of three months in the hospital, and in the following weeks and months, Beth managed to get almost every type of complication you can get, including the ongoing MRSA infection, and a number of viral infections (treatments for which caused her body to swell uncomfortably with retained fluids), and she came very close to death.

Fortunately, that phase came to an end. Ongoing Chimerism tests have confirmed that her leukemia has not made a reappearance. As I write this, we are about 10 months out from the transplant. And the good news is, her body has healed over time. I told her shortly after the transplant, “you may feel terrible, but you don’t have leukemia any more”.

We are grateful to live at a time when medical science can offer such a promising, if complicated cure to what would surely have been a deadly disease.

**Challenge 5: The Financial Complications**

The various leukemia organizations offered plenty of helpful advice for dealing with insurance and other financial issues, but there are no easy solutions. My employer, Black Box Corporation in Pittsburgh, PA offered an excellent health insurance package. They also worked with me to obtain the necessary Family Medical Leave Act (FMLA) time off.
Through this whole process, Beth did not work because she was physically not strong enough, and I had to take a great deal of time off, to take her back and forth to doctor’s appointments, and to spend time in the hospital. That meant we were going without one of our two incomes for a long time, and both of our two incomes for at least several months.

Apart from the notion that my wife could die from this process, the financial challenges were the most frightening for me. And I have to say, frankly, that most of the financial advice that was offered was, while well-intentioned, not very helpful.

After the transplant, the Social Worker at the Hospital worked with us to file for Social Security disability payments. It didn’t take long for this application to be processed (although you must wait five months after your last day of work before you can apply for it). This amounted to half of what she had been earning while working full time. Beth has also applied to the Veterans Administration for disability benefits; as I write, this application is still being processed some 10 months later.

But it was the people who knew us and who we interacted with on a regular basis who helped us the most.

Organizations such as the MDS Foundation... provide information that helps people to sort through all the ramifications of this unsettling diagnosis and give hope...

The vast majority of the financial help that we received came from private donations, after I had asked for it. My co-workers took up several collections. I had a personal blog, and I set up a Paypal account through which we could take private donations. Other bloggers as well helped us make our appeal for financial help.

Some teachers in the local elementary school our daughter attends chipped in with some fundraising activities. The school purchased Christmas gifts for our family, and a “Bowling for Bethany” event in April raised several thousand dollars for us.

Several churches made financial contributions to us. Our own home church was probably the biggest financial help throughout the process. In addition to helping us with rides to various appointments, they actually purchased a freezer for us, brought prepared, frozen meals on a regular basis, and made our mortgage payment for us for the better part of a year.

Concluding Considerations

“You have a blood tumor” is not the kind of thing anyone wants to hear. In just the last 10 years, advances in genetic science have greatly increased what is known about the various types of leukemias, and their various treatments. And MDS, formerly simply known as “pre-leukemia,” itself now understood to be a complex of maladies with a bewildering array of possible causes, symptoms, and treatment options.

Organizations such as the MDS Foundation, the Leukemia and Lymphoma Society, and the National Marrow Donor Program (marrow.org) all provide information that helps people to sort through all the ramifications of this unsettling diagnosis and give hope to patients and their families.

The greatest amount of help still came from the doctors and nurses we dealt with on a daily basis, and the friends and churches in our various communities who took up our cause and spread the word, “Bethany Bugay, an Iraq war veteran, has a form of leukemia, and she needs your help.”

Thanks to their help, we now have hope for the future.

Connect on our PATIENT FORUM

Don’t miss out on our MDS Patient Forum! This feature hosted by the MDS Foundation and monitored by health professionals is a free online discussion board of information exchanged between patients, caregivers, and family members.

Connect today at www.mds-foundation.org
My MDS Story

My name is Keith Hennig and on February 22, 1993 my father died of acute leukemia. He had refractory anemia that summer and my mother was a nurses’ aid and her friend, the local doctor, told her that this was what his father had died from and to anticipate that this would be Dad’s last Christmas. The refractory anemia would manifest into acute leukemia and he would die very soon after that. I received this information after Christmas and Dad got sick in early February. His direct involvement in our lives ended that February. However, as many people may have experienced, when you lose a parent you sort of re-evaluate your life and tell yourself that when you get the chance to do things for the groups that have helped or could have helped you make an effort to do so. My Dad’s first wife died of breast cancer and he and my mom were always the neighborhood American Cancer Society drive leaders. You can sort of say that I have followed in their footsteps and have done the same thing now that I am married and have a family of my own.

I live in a small town in Wisconsin, pretty much like the one in Iowa I grew up in, and I love them both. This is the first place I have really called home since leaving my parents. I served on several city boards and made friends with other board members. One of those board members was Ron Carlsen. Ron and I served on the City Park Board for about 5 years together. I eventually moved out of the city limits but still live in the great community, and Ron and I go to the same church. One day he was on the prayer list, and when I found out it was MDS it was a real gut punch. I knew what comes next, you just die. So the next summer when Ron was putting together a benefit to sign up marrow donors, and was still alive and kicking, I went in and got on the list as a donor and asked him how it worked. I found out about the amazing network of MDS donors and the MDS Foundation. I have to say I was and still am impressed.

If my father had gotten sick in 2010 rather than 1993, I am much more confident he would be here today.

I like to volunteer. I am a Boy Scout and Venture Crew leader, a swim coach, and one of the youth leaders at St. John’s Lutheran Church (sort of the un-churched youth leader). This past summer while working on getting in better shape for my scouts’ backpacking trip to Glacier National Park, my wife managed to get me signed up for a local version of “The Biggest Loser”. I needed it. Not being one to not take advantage of a good opportunity, I got sponsors to help me pay for what is actually a fairly expensive little weight loss program. Once involved in this program, I wanted to see what I could do to raise some money for a good cause. The first one that came to mind was the MDS Foundation – the group that helped my friend Ron, and that could have quite likely saved my dad if they, and the technology, had been available then. I sent out emails to all the groups I help with and got several to pledge dollars for pounds of weight lost. With donations ranging from $.25 per pound to “Put me down and we’ll see how you do” I was eventually raising money for MDS. I did not get involved with all this to lose weight, just to get in shape to make it over the mountains without keeling over. My idea of teaching boy scouts first aid is not having a heart attack 10 miles from the nearest road! However, I found that knowing that I was finally able to do something for Dad, even after he was dead, was pretty inspiring. I had lost about 9 lbs. before I got involved with the other “Fat Losers” (I thought it was a funny nickname but I am not sure all my compatriots were amused) and then lost another 51.4 lbs., 21.13% of my body weight during the competition. I managed to raise just over $1,000.00 for MDS. I have a couple of friends with the audacity to challenge me that they will double their pledge if I keep the weight off for the next 6 months! Well, I am down a couple more pounds and don’t plan on stopping my fitness journey. I am signed up to do a 5K on Thanksgiving Day. I figure that way I can have mashed potatoes and gravy with my turkey! Dad liked taters and gravy and I think he would appreciate that.

Everybody dies but not everybody truly lives. My father died when he was 68 years old and I was 26. He had made it to 68 with an 8th grade education and left my mother a widow for the second time in her life. Since he died she has not wanted for anything. Finances have never been a worry for her. To put it into perspective, Dad heated our home with wood that he cut, and after his death it took almost 8 years before Mom burned through all he had cut, split and prepared. She spends her time enjoying the love and respect of her children, grandchildren, great grandchildren, and other friends and relatives. That is an impressive legacy and I have a responsibility to live up to it.

Thank you MDS Foundation for being there for all the parents and for their children who will get to have another Christmas with one another as a result of your work. On a slightly more personal note, thank you for helping me to eliminate some of the helplessness, both mine and that of the families of those stricken with MDS. I prefer a life sentence to a death sentence any day!

This is a “before” and “after” shot of me.
Nursing in MDS

International MDS Foundation Nurse Leadership Board

Erik Aerts, RN
Nurse Manager
University Hospital Zürich
Internal Medicine-Oncology
Stem Cell Transplantation Ward and
Polyclinic Haematology/Apherese/
Stem Cell Transplantation
Zürich, Switzerland

Louise Arnold, RN
Clinical Nurse Specialist
Department of Haematology
St James’s Institute of Clinical Oncology
Leeds, United Kingdom

Angelika Bitter, RN
Universitätsklinikum Carl Gustav Carus
Dresden, Germany

Claudia Boglione, RN
Stem Cell Transplantation Nurse Mentor
University Hospital Careggi
Florence, Italy

Núria Borràs, RN
Hematology-Oncology Nurse
ICMHO Hospital Clinic
Barcelona, Spain

Karen Campbell, BSc(Hons), RN, MN, PGcert
Macmillan Lecturer/Practitioner in Cancer Nursing
Teaching Fellow
Edinburgh Napier University
Edinburgh, Scotland, United Kingdom

Debbie Carr, RN, Ba OH&S
Nursing Unit Manager
Haematology Day Unit
Calvary Mater Hospital
Newcastle, Australia

Nicole Crisp, MN, NP
Nurse Practitioner, Hematology
University of Alberta Hospital
Edmonton, Alberta, Canada

Erin Demakos, RN, CCRN
Administrative Director
Myelodysplastic Disease Center and MPD Program
Mount Sinai School of Medicine
New York, New York, United States

Corien Eeltink, RN, MA ANP
Nurse Practitioner
Department of Haematology
VU University Medical Center
Amsterdam, The Netherlands

Lenn Fechter, RN
Nurse Coordinator,
Department of Hematology
Stanford Hospital and Clinics
Stanford, California, United States

Janet Hayden, RN, BSc(hons), MPH
Myeloid Clinical Nurse Specialist
Haematological Medicine
Kings College NHS Foundation Trust
London, United Kingdom

Emily A. Knight, RN, BSN, OCN
Hematology Registered Nurse Coordinator
Mayo Clinic
Scottsdale, Arizona, United States

Sandra E. Kurtin, RN, MS, AOCN, ANP-C
Hematology/Oncology Nurse Practitioner
The University of Arizona Cancer Center
Adjunct Clinical Assistant Professor of Nursing
Clinical Assistant Professor of Medicine
University of Arizona
Tucson, Arizona, United States

Petra Lindroos Kolqvist, RN
Teamleader, Anemia Leukemia Team
Department of Hematology and Coagulation
Sahlgrenska University Hospital
Goteborg, Sweden

Arno Mank, RN
President EBMT Nurses Group
European Group for Blood and Marrow Transplantation
Nurse Researcher
Academic Medical Centre
Amsterdam, The Netherlands

Sara M. Tinsley, ARNP, AOCN
Malignant Hematology Nurse Practitioner
H. Lee Moffitt Cancer Center
Tampa, Florida, United States

New Resources for Nurses

We are pleased to announce the launch of our Nursing Portal on the MDS Foundation website, a free resource developed to provide the nursing community with materials to help communicate with and support their patients with MDS. Access http://www.mds-foundation.org/nursing-portal to view our comprehensive set of resources. Here you can view the presentation slides and audio presentations of our educational symposium presented in New Orleans.
Would you like your treatment center to become part of the referral system for MDS patients and be designated as a Center of Excellence? To be recognized as a Center of Excellence, an institution must have the following:

- An established university (or equivalent) program
- Recognized morphologic expertise in MDS
- Available cytogenetics and/or molecular genetics
- Ongoing research, including Institutional Review
- Board–approved clinical trials
- Documentation of peer-reviewed publications in the field

Please contact the Foundation for further information and an application form for your center.

The following centers have qualified as MDS Centers of Excellence:

**UNITED STATES**

**ARIZONA**
- Mayo Clinic Hospital
  Scottsdale, Arizona
- Ruben Mesa, MD/James Slack, MD/
  Raoul Ties, MD, PhD
- The University of Arizona
  Cancer Center
  Tucson, Arizona
  Ravi Krishnaswami, MO, FACCP

**CALIFORNIA**
- Cedars-Sinai Medical Center
  UCLA School of Medicine
  Los Angeles, California
  H. Phillip Koeffler, MD
- City of Hope National Medical Center
  Duarte, California
  Stephen J. Forman, MD
- Moores Cancer Center at the
  University of California, San Diego
  Rafael Bejar, MD, PhD
- Peter Curtin, MD
- Stanford University Medical Center
  Stanford, California
  Peter L. Greenberg, MD
- UCLA Center for Health Sciences
  Los Angeles, California
  Gary J. Schiller, MD
- University of Southern California
  Keck School of Medicine
  Los Angeles, California
  Casey L. O’Connell, MD

**FLORIDA**
- All Children’s Hospital
  St. Petersburg, Florida
  Gregory Hale, MD
- Mayo Clinic
  Jacksonville, Florida
  James M. Foran, MD
  Alvaro Moreno-Aspitia, MD
- Sylvester Comprehensive Cancer Center
  University of Miami Miller School of Medicine
  Miami, Florida
  Stephen D. Nimer, MD
- University of Florida Shands Hospital
  Gainesville, Florida
  Christopher R. Cogle, MD
- University of South Florida
  H. Lee Moffitt Cancer Center
  Tampa, Florida
  Alan F. List, MD

**GEORGIA**
- Emory Winship Cancer Institute
  Emory University
  School of Medicine
  Atlanta, Georgia
  Amelia Langston, MD
- The Blood and Marrow Transplant
  Program at Northside Hospital
  Atlanta, Georgia
  Asad Bashey, MD

**ILLINOIS**
- Loyola University Chicago
  Catholic University
  Maywood, Illinois
  Scott E. Smith, MD, PhD
- Robert H. Lurie Comprehensive
  Cancer Center of Northwestern University
  Feinberg School of Medicine
  Chicago, Illinois
  Olga Frankfort, MD
- Rush University Medical Center
  Chicago, Illinois
  Jamile Shamo, MD
- University of Chicago
  Medical Center
  Chicago, Illinois
  Richard A. Larson, MD

**INDIANA**
- Indiana University
  Simon Cancer Center
  Indianapolis, Indiana
  Larry Crone, MD
  Hamid Sayar, MD, MS

**MARYLAND**
- Johns Hopkins University
  School of Medicine
  Baltimore, Maryland
  Steven D. Gore, MD
- University of Maryland
  Greenebaum Cancer Center
  Baltimore, Maryland
  Maria R. Baer, MD

**MASSACHUSETTS**
- Children’s Hospital Boston
  Boston, Massachusetts
  Inga Hofmann, MD
- Dana-Farber Cancer Institute
  Boston, Massachusetts
  Richard M. Stone, MD/David P. Steensma, MD
- Tufts University School of Medicine
  Tufts Medical Center
  Boston, Massachusetts
  Kellie Sprague, MD

**MICHIGAN**
- Mayo Clinic
  Rochester, Minnesota
  Mark R. Litzow, MD
- University of Minnesota
  Medical School
  Fairview University of Minnesota
  Medical School
  Minneapolis, Minnesota
  Erica D. Warlick, MD

**MINNESOTA**
- Mayo Clinic
  Rochester, Minnesota
  Mark R. Litzow, MD
- University of Minnesota
  Medical School
  Fairview University of Minnesota
  Medical School
  Minneapolis, Minnesota
  Erica D. Warlick, MD

**MISSISSIPPI**
- Washington University
  School of Medicine
  Siteman Cancer Center
  St. Louis, Missouri
  John F. DiPersio, MD, PhD

**NEBRASKA**
- University of Nebraska Medical Center
  Omaha, Nebraska
  Lori Maness, MD

**NEW JERSEY**
- The Cancer Center of Hackensack
  University Medical Center
  Hackensack, New Jersey
  Stuart Goldberg, MD

**NEW YORK**
- Albert Einstein College of Medicine
  Cancer Center
  Bronx, New York
  Amit Verma, MD
- Columbia University Medical Center
  New York, New York
  Azra Raza, MD
- Memorial Sloan-Kettering Cancer Center
  New York, New York
  Virginia M. Klimke, MD
- Monter Cancer Center /
  NSLU Cancer Institute
  Lake Success, New York
  Steven L. Allen, MD
- Mount Sinai School of Medicine
  New York, New York
  Lewis R. Silverman, MD
- New York Medical College/
  Westchester Medical Center
  Valhalla, New York
  Karen Seiter, MD

**OHIO**
- Cleveland Clinic Foundation
  Taussig Cancer Center
  Cleveland, Ohio
  Jaroslaw Maciejewski, MD, PhD
- Duke University Medical Center
  Durham, North Carolina
  Carlos M. deCastro, MD
- Wake Forest University
  School of Medicine
  Comprehensive Cancer Center
  Winston-Salem, North Carolina
  Bayard L. Powell, MD
- University of Rochester Medical Center
  Rochester, New York
  Jane L. Liesveld, MD

**TENNESSEE**
- Vanderbilt University Medical Center
  Nashville, Tennessee
  Mark R. Litzow, MD

**TEXAS**
- MD Anderson Cancer Center
  Houston, Texas
  Cheryl L. Heading, MD
- University of Texas MD Anderson
  Cancer Center
  Houston, Texas
  Cheryl L. Heading, MD

**UTAH**
- Huntsman Cancer Institute: Utah Medical Center
  Salt Lake City, Utah
  John T. Burt<br>
The Ohio State Comprehensive Cancer Center, James Cancer Hospital and Solove Research Institute
Columbus, Ohio
Alison R. Walker, MD

Pennsylvania
The Western Pennsylvania Cancer Institute
Pittsburgh, Pennsylvania
James M. Rossetti, DO

Thomas Jefferson University Kimmel Cancer Center
Philadelphia, Pennsylvania
Emmanuel C. Besa, MD

University of Pennsylvania Cancer Center
Philadelphia, Pennsylvania
Selina Luger, MD

Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee
Madan Jagasia, MD
Stephen Strickland, MD

Texas
Cancer Care Centers of South Texas
San Antonio, Texas
Roger Lyons, MD

Southwest Regional Cancer Center
Austin, Texas
Richard Helmer, III, MD

University of Texas MD Anderson Cancer Center
Houston, Texas
Guillermo García-Manero, MD
Hagop Kantarjian, MD

Washington
Fred Hutchinson Cancer Research Center
University of Washington
Seattle, Washington
Joachim Deeg, MD/Elihu Estey, MD

Washington, DC
Georgetown University Hospital Lombardi Comprehensive Cancer Center
Washington, D.C.
Catherine Broome, MD

Wisconsin
Medical College of Wisconsin Bone Marrow Transplant Program
Milwaukee, Wisconsin
Parameswaran Hari, MD

University of Wisconsin Madison Medical School
Madison, Wisconsin
Mark B. Juckett, MD

Outside the United States

Argentina
Sanatorio Sagrado del Corazón
Buenos Aires, Argentina
Marcelo Iastrebner, MD

Australia
Peter MacCallum Cancer Institute
University of Melbourne
East Melbourne, Australia
John F. Seymour, MD

University of Tasmania
Royal Hobart Hospital
Hobart, Tasmania, Australia
Raymond M. Lowenthal, MD

University of Wisconsin Hospital of Innsbruck
Innsbruck, Austria
Reinhard Stauder, MD

Medical University of Vienna
Vienna, Austria
Peter Valentin, MD

Belgium
AZ Sint-Jan AV
Brugge, Belgium
Dominik Seleslaj, MD

University Hospital Leuven
Leuven, Belgium
Michel Deforgé, MD, PhD

Brazil
AC Camargo Hospital – Cancer Center
São Paulo, Brazil
Lúiz Fernando Lopes, MD, PhD

Hemocentro da UNICAMP
University of Campinas
Campinas, Brazil
Irene Lorand-Metz, MD

Servicio de Hematología do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
São Paulo, Brazil
Elvira R.P. Veloso, MD, PhD

Universidade Federal de Ceará
Ceará, Brazil
Silvia Maria M. Magalhães, MD, PhD

Universidade Federal de São Paulo
São Paulo, Brazil
Maria de Lourdes Chaufaide, MD, PhD

Canada
Princess Margaret Hospital
Toronto, Ontario, Canada
Karen Yee, MD

Toronto Sunnybrook Regional Cancer Centre
Toronto, Ontario, Canada
Richard A. Weller, MD

University of Toronto Hospital for Sick Children
Toronto, Ontario, Canada
Yigal Dror, MD

China
Institute of Hematology and Blood Diseases Hospital
Chinese Academy of Medical Sciences
Tianjin, China
Zhiyan Xiao, MD

Czech Republic
Institute of Hematology & Blood Transfusion
Prague, Czech Republic
Jaroslav Cermák, MD, PhD

Denmark
Odense University Hospital
The University of Southern Denmark
Odense, Denmark
Gitte Birk Kønndrup, MD

Rigshospitalet National University Hospital
Copenhagen, Denmark
Lars Kjeldsen, MD, PhD

University of Århus
The University Hospital Århus, Denmark
Mette Sølv Holm, MD, PhD

France
Centre Henri Becquerel
Rouen University School of Medicine
Rouen, France
Aspasia Stamatooulas, MD

Centre Hospitalier Universitaire (CHU) de Angers
Service des Maladies du Sang
Angers, France
Norbert Ihah, MD

Centre Hospitalier Universitaire (CHU) de Grenoble
Grenoble, France
Jean-Yves Cahn, MD

Centre Hospitalier Universitaire (CHU) de Limoges
Hôpital Dupuytren
Limoges, France
Dominique Bondessoile, MD

Centre Hospitalier Universitaire (CHU) de Nancy
Nancy, France
Agnès Guerci-Bresler, MD, PhD

Centre Hospitalier Universitaire (CHU) de Tours
Hôpital Bretonneau
Tours, France
Emmanuel Gyan, MD, PhD

Hôpital Avicenne/
University Paris XIII
Bobigny, France
Pierre Fenaux, MD

Hôpital Cochin/
University Paris V
Paris, France
Francois Dreyfus, MD

Hôpital Saint Louis/
University Paris VII
Paris, France
Christine Chomienne, MD, PhD

Hôpital Vallier/
University Paris X
Paris, France
Norbert Vey, MD

Service des Maladies du Sang
Hôpital Claude Huriez
Lille, France
Bruno Quenrez, MD

Germany
Georg-August-Universität Göttingen
Göttingen, Germany
Dietlef Haase, MD, PhD

Hannover Medical School
Medizinische Hochschule Hannover
Hannover, Germany
Arnold Ganser, MD

Heinrich-Heine Universität Düsseldorf
University Hospital Düsseldorf, Germany
Ullrich Germain, MD

Johann Wolfgang Goethe Universität
Frankfurt Main, Germany
Gesine Bug, MD

Klinikum Rechts der Isar
Technical University of Munich
Munich, Germany
Katharina Götz, MD

MLL Münchner Leukämielabor
Munich, Germany
Torsten Hafnerich, MD

St. Johannes Hospital
Heinrich-Heine Universität
Düsseldorf, Germany
Carlo Au, MD, PhD

University of Heidelberg Medical Center, St. Lukas Klinik Solingen
Solingen, Germany
Ullrich Mahlmecht, MD, PhD
New Research Protocol Listing

NATIONAL CANCER INSTITUTE TRIALS

As we go to press the National Cancer Institute (NCI) has listed more than 100 clinical trials that focus on myelodysplastic syndromes. Full study information on these trials is available at www.cancer.gov. This information includes basic study information, study lead organizations, study sites, and contact information. To access the information:

- Log on to www.cancer.gov
- Click on “Search for Clinical Trials”
- Click on “Type of Cancer” and type in ‘myelodysplastic syndromes’
- Hit search

This search will provide you with all the trials currently underway in MDS. You may also sort by trials that only focus on treatment or trials that only focus on supportive care.

To view listings of additional studies you can log onto www.clinicaltrials.gov. For telephone support, call the National Cancer Institute at 1-800-4-CANCER.

Announcing New Clinical Trials

NAME OF INSTITUTION: Novartis Pharmaceuticals
TRIAL NUMBER: NCT00940602
Title of Trial or Description: Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study (TELESTO)
A Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial of Deferasirox in Patients With Myelodysplastic Syndromes (Low/Int-1 Risk) and Transfusional Iron Overload
Currently Recruiting Participants.
The primary purpose of this study is to prospectively assess the efficacy and safety of iron chelation therapy with deferasirox compared to placebo in patients with myelodysplastic syndromes (low/int-1 risk) and transfusional iron overload.
Contact the Novartis Clinical Trials Hotline at 800-340-6843 or go to www.clinicaltrials.gov for additional information and to view the active sites.

NAME OF INSTITUTION: Celgene Corporation
TRIAL NUMBER: NCT01029262
Title of Trial or Description: A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q (MDS-005)
Currently Recruiting Participants.
The primary purpose of this study is to compare the efficacy of Lenalidomide (Revlimid®) versus placebo in achieving red blood cell transfusion independence in the overall study population and in a pre-specified subgroup of patients with an erythroid differentiation gene expression signature predictive of Lenalidomide response.

Access is Key to Treatment

The MDS Foundation Will Provide Location Information for the Rigosertib (ESTYBON® ON 01910.Na) MDS Clinical Trial

ONTIME: Study Description (ON 01910.Na TRIAL IN MYELODYSPLASTIC SYNDROME)
A phase III study of rosiglitab (Estybon®, ON 01910.Na) in myelodysplastic syndrome (MDS) patients after Vidaza® (azacitidine) or Dacogen® (decitabine) treatment. Rigosertib is a novel mitotic inhibitor of PLK and PI-3 kinase pathways.

The ONTIME MDS clinical trial is accessible at a wide variety of locations and key medical centers.
To find a trial site in your area where this study is being conducted, please visit http://mdsclinicaltrial.com/oncology-trials/ontime-study/site-locations/.

Consider the ONTIME Trial for the Treatment of MDS Patients after Azacitidine or Decitabine
– Accrual of patients is ongoing
If you are a physician or nurse and would like to refer a patient for enrollment into this clinical trial please contact the MDS Foundation at 800-MDS(637)-0839.

Learn more at
ASH 2012
Georgia World Congress Center
Atlanta Georgia
December 8–11th
Visit BOOTH 2307!

Learn More –
More information can be found at www.mdstrial.com or clinicaltrials.gov, the identifier is NCT01241500
Thank You!

The MDS Foundation relies entirely on gifts and membership fees to further its work. We would like to acknowledge the generosity of the following individuals and organizations that have recently provided gifts to the Foundation:

Elizabeth Pecknold  
Vancouver, BC, Canada

Milford & Zita Desenberg  
Sarasota, FL

Mariana Dagatti  
Newton, MA

James Dowd  
Stuart, FL

Hildred C. Pehrson  
Livermore, CA

Eileen Dunne  
Kingston, MA

Peter Finciello  
Jamaica, NY

Thomas & Joanne Kubiak  
Centennial, CO

Lorenzo & Filomena Diurno  
Wilton, CT

Jim & Chris Maier  
Palos Verdes Pnsla, CA

Audrey H. Gabel  
Salinas, CA

Ross Jackson, Carmi, IL

FINRA Employees, WPG SOLUTIONS, INC. on behalf of FINRA  
Tacoma, WA

Meredith Bruce  
Mill Valley, CA

Dr. Kathleen De Lorenzo  
Maumelle, AR

Larry Schneider  
Aventura, FL

Stephanie Ross-Evans  
Superior, WI

The Kaliher Family  
Blaine, MI

Lynn Ross  
New Brighton, MN

John Vogland  
Hudson, WI

Ernest Ulrich  
New York, NY

Mary Ellen Kelly  
Inverness, IL

West Boca Raton Comm. High School  
The School District of Palm Beach County, Florida  
Boca Raton, FL

Marjorie L. Mann  
San Antonio, TX

Carla Mercado  
San Antonio, TX

Ronald J. Vanskiver  
Nothingham, MD

Frederic Leverenz  
Gilbert, AZ

Jay Biggs, Greenwood, DE

Jerry Oliver  
Granville, OH

Nathan Cedars  
Stephenville, TX

Stephen and Catherine Heft  
Boca Raton, FL

Blair and Norine Novy  
Boca Raton, FL

John M. Sweet and Nicola Boyd  
Headwaters Farm  
Middlebrook, VA

James B. Harris  
Barrie, ON, Canada

Lorraine B. Gleixner  
Greenwood, IN

Stephanie Ross-Evans  
Superior, WI

Delos R. Goddard  
Colorado Springs, CO

Kevin J. Lawlor  
Warrington, PA

Yilmaz Hassan  
Howell, NJ

Wayne Sether  
St. Paul, MN

Augustus Harrison Tulloss  
Rocky Mount, NC

West Boca Raton Comm. High School  
Boca Raton, FL

Jalil Fardanesh  
Folsom, CA

Grifols Therapeutics, Inc., RTP  
North Carolina

Tracey L. Hill  
Alexandra Schwartz  
New York, NY

Audrey Hassan  
Howell, NJ

Marilyn J. Litvin  
Framingham, MA

Mary Benson  
Orem, UT

John Wilmelmi  
Boston, MA

Adept Consumer Testing  
Beverly Hills, CA

Isabel Calderon  
Irvine, CA

Leopold LeBlanc  
Silver Springs, FL

William A. Roberts  
Naples, FL

Rose Robustellini  
Lodi, NJ

Florence Gilmartin  
Sanford, FL

Maureen Pavlik, Odell, NE

Barbara Leonardo  
Sebastian, FL

David and Carol Usher  
Colchester, VT
National Nurses Day
A tribute gift has been made to the MDS Foundation in honor of Nurse Sandra E. Kurtin
Donated by Max Atwell,
Tucson, AZ
who appreciates your skill, care and commitment.

R. George and Genevieve Angulo
Sun Lakes, AZ
Eunice Edgington, Rohnert Park, CA
Victoria Sadler
Harwinton, CT
Joe Artuso, Berwyn, PA
Frances Gillen, Sparta, TN
Jalil Fardanesh
Folsom, CA
Marlene Strohi, San Marcos, CA
Congregation (Jacobs Ladder)
Maple Glen, PA
Richard and Carolyn Sendler
Columbia, SC
Barbara Bryson Young
Waxahachie, TX
Emily Rubenstein
Winter Park, FL
Gayle Leitman, Mtn. Brook, AL
Margaret Haskell
Grantham, NH
Mariette Van Engelen
Thomton, CO
Clement & Joan Rancourt
Plantsville, CT
Tracey L. Hill
Steven Pepperman, New York, NY
Dr. Sol and Trudy Klioze
East Lyme, CT
Steve Gold, Glenmont, NY
Rob Skirboll, Greensboro, NC
Colleen Vevang

Jonathan A. Steele
North Charleston, SC
Delos R. Goddard
Colorado Springs, CO
Joseph J. Costa
Sleepy Hollow, NY
Robert Cohn
Palm Beach Gardens, FL
David Hensel
Oak Forest, IL
Ross Jackson, Carmi, IL
Angela Sudol
Elmwood Park, NJ
D.O. Totty, Collierville TN
Gerald C. Clements
Naples, ME
Robert Bryson, San Diego, CA
Leonard Bini
Fallbrook, CA
Judith Klick, Myrtle Beach, SC
Adrian E. Ricca
Weirton, WV
Edward Carmody, Carson, CA
Thomas J. O’Keefe
Newport Beach, CA
Joan R. Dorf, Rockville, MD
Clement & Joan Rancourt
Plantsville, CT
Caterina Caron
Jacksonville, FL
Marilyn S. Gould
St. Petersburg, FL
Joni Sitko, Elysburg, PA
Robert M. Wester
Destin, FL
Richard A. Osborne
Kingwood, TX
Ron Ferrara, Pasadena, CA
Sheila Martin
Fairfax, VA
Ernest Ulrich, New York, NY
Armando R. Ruiz
Huntington Beach, CA
V.R. “Spin” Nelson, Lakewood, CO
Allison Myslinski
Maryland Heights, MO
William Shulevitz, New York, NY
Chris and Tara Killgore
Portland, OR
Ronald L. Rapaport
Potomac, MD
Pat Shirley, Golden CO
Edward Daniels
Raleigh, NC
Mary Imperioli
Sandy Hook, CT
Carol Full
Springfield, VA
Nancy D. Artley
Towson, MD
Tom Mastandrea
Lincolnshire, IL
Michael & Sharon Tier
Conshohocken, PA
Ina Block, Napa, CA
Rita Paul, Naples, FL
Martina Wiedmayer
Collegeville, PA
Marjorie L. Mann
Karen Werner, West Islip, NY
Jerry McMurray
Knoxville, TN
William Vault
Washington, DC
Margaret H. Wiedmayer
Philadelphia, PA
Daniel and Andrea Reese
Cataula, GA
Nora Wrzesinski, Greenville, NC
Jean C. Forsell, Forest Lake, MN
Duane R. Bogenschneider
Mequon, WI
Tom and Joanne Kubik
Centennial, CO
Stanley Rudick, Sparks, MD
Roger R. Hewitt, Smithville, TX
Redencion Bote Lustre
The Villages, FL
In Memoriam

A memorial fund has been established in the name of Mr. Edward Agolia
Donations have been made in Mr. Agolia’s memory by:
Robert and Theresa Sheldon, Geneva, OH

A memorial fund has been established in the name of Mr. Patrick M. Alfe
Donations have been made in Mr. Alfe’s memory by:
Rich and Eileen Weaver Widenwer University
Coatesville, PA Chester, PA
Fred and Regina Helm Victoria Afle
East Falkowxfield, PA Brookhaven, PA
Marge Kelly Joseph and Lisa Wolflington
Lansdowne, PA Philadelphia, PA
George and Nancy Hassel Frank & Dolores Castellucci
Glenolden, PA Philadelphia, PA
Robert and Marie Redfern
Brookhaven, PA

A memorial fund has been established in the name of Dr. John D. Anderson
Donations have been made in Dr. Anderson’s memory by:
Robert and Barbara McGhee, Ocala, FL

A memorial fund has been established in the name of Aunt Sara
Donations have been made in Aunt Sara’s memory by:
Jerry and Renee Green, Wildwood Crest, NJ

A memorial fund has been established in the name of Mrs. Cathy Jean Avants
Donations have been made in Mrs. Avants’ memory by:
Mary Warner-Bartella, Sun City, AZ

A memorial fund has been established in the name of Mr. George J. Balint
Donations have been made in Mr. Balint’s memory by:
Stephen and Barbara Wheeler Dean and Paula Squires
Buckingham, VA Middletown, VA

A memorial fund has been established in the name of Mr. William Ball
Donations have been made in Mr. Ball’s memory by:
Peter and Mary Navarro, Downingtown, PA

A memorial fund has been established in the name of Mr. John L. Barnhart, Jr.
Donations have been made in Mr. Barnhart’s memory by:
Ricky Barnhart, Hilliard, OH

A memorial fund has been established in the name of Mr. Freddie Arnold “Jerry” Barr
Donations have been made in Mr. Barr’s memory by:
Mary Barr, Gardendale, AL

A memorial fund has been established in the name of Mr. Wayne J. Bender
Donations have been made in Mr. Bender’s memory by:
Paula Gevaudan, Annapolis, MD

A memorial fund has been established in the name of Ms. Bea Besette
Donations have been made in Ms. Besette’s memory by:
Ruth Nicoll
South Ealing, London, UK

A memorial fund has been established in the name of Mr. Wayne Vincent Black
Donations have been made in Mr. Black’s memory by:
Dona Sue Black Cool
Columbia, MO

A memorial fund has been established in the name of Mr. John M. Blasiak
Donations have been made in Mr. Blasiak’s memory by:
Judy Armstrong
Hamden, CT

A memorial fund has been established in the name of Mrs. Sandra Lynn “Sandy” Bolar
Donations have been made in Mrs. Bolar’s memory by:
Marc and Amy Nile
Cincinnati, OH
Gary and Suzanne Hatten
Bethany, MO
James and Janis Erland
Lawrence, KS
Weldon and Nyla Whiteaker
Schaumburg, IL
Kent and Martha White
Cedarburg, WI
Audrey E. Thorkelson
Phoenix, AZ
Elizabeth Eifler
Gilbert, AZ
Jack and Kay Ann Feiden
Wichita, KS
Dick Anderson & Fran Belden
Wichita, KS
Charles and Rita McCall
Marcia Graul, Lincoln, NE
Larry & George Ann Seymour
Bella Vista, AR
Janice E. Stites
Wichita, KS
Gene McMichael
Kansas City, MO
Julia MacLachlan
Prarie Village, KS
Jean Scott
Tulsa, MACAU
Ray and Susan Fritzemeyer
Wichita, KS
Lois Hubbard
Wichita, KS

A memorial fund has been established in the name of Mrs. Ruth Borchardt
Donations have been made in Mrs. Borchardt’s memory by:
Lawrence Doian
Helena, MT
Dennis & Terri Hirschbrunner
Columbus, NE

A memorial fund has been established in the name of Mr. Joe Boyd
Donations have been made in Mr. Boyd’s memory by:
Karen Boyd, St. Louis, MO

A memorial fund has been established in the name of Mr. Jack Brennan
Donations have been made in Mr. Brennan’s memory by:
William Hansen, Eagan, MN

A memorial fund has been established in the name of Ms. Harriet Brenner
Donations have been made in Ms. Brenner’s memory by:
Candice Stark, Los Altos, CA

A memorial fund has been established in the name of Mr. Robert Brody
Donations have been made in Mr. Brody’s memory by:
Bruce and Ede Weiner
Houston, TX
Curt and Connie Krueger
Lincolshire, IL

A memorial fund has been established in the name of Mr. Jesse H. “Red” Brown
Donations have been made in Mr. Brown’s memory by:
Bill and Betty Milner
Charlotte, NC
Cohen and Susie Gaskins
Avin, SC
Richard W. Salmons, Jr.
Charleston, SC
John and Lila Smith
Bonneau, SC

A memorial fund has been established in the name of Mr. Clem Cahalli
Donations have been made in Mr. Cahalli’s memory by:
Claire-Elizabeth Sloan
Portland, OR

A memorial fund has been established in the name of Mr. Joseph “Joe” Calandro
Donations have been made in Mr. Calandro’s memory by:
Mark and Leah Ralph, Vergennes, VT

A memorial fund has been established in the name of Mr. Roy C. Carter
Donations have been made in Mr. Carter’s memory by:
Abbie C. Carter
Philadelphia, PA

A memorial fund has been established in the name of Doctor Vincent J. Catanzarro
Donations have been made in Dr. Catanzarro’s memory by:
Vanessa Catanzarro
Township of Washington, NJ
A memorial fund has been established in the name of
**Ms. Sarah T. Cecil**
Donations have been made in Ms. Cecil’s memory by:
- William M. Harris, Burlington, NC
- Aileen Shinaman
- George and Jennifer Clever, Rochester, NY
- Susan Leahy, Rochester, NY
- Lisa Hutto, Fort Lee, NJ
- Bud & Roberta Geisenheimer
- Lake Katrine, NY

A memorial fund has been established in the name of
**Mrs. Peggy Cruse**
Donations have been made in Mrs. Cruse’s memory by:
- William M. Harris, Burlington, NC

A memorial fund has been established in the name of
**Mr. Edward S. Dale**
Donations have been made in Mr. Dale’s memory by:
- William McGahern, Miami, FL

A memorial fund has been established in the name of
**Mr. Alessandro Degl’Innocenti**
Donations have been made in Mr. Degl’Innocenti’s memory by:
- Roberto Degl’Innocenti, Miami, FL

A memorial fund has been established in the name of
**Mr. Leonard Dickstein**
Donations have been made in Mr. Dickstein’s memory by:
- Rodney and Joni Falk, Newton, MA

A memorial fund has been established in the name of
**Mr. Arthur H. “Bushy” Epstein**
Donations have been made in Mr. Epstein’s memory by:
- Brian and Laura Becker, West Hartford, CT

A memorial fund has been established in the name of
**Mr. Alfred J. Everett**
Donations have been made in Mr. Everett’s memory by:
- Patricia Everett, Wilmington, NC

A memorial fund has been established in the name of
**Ms. Eleanor Z. Falco**
Donations have been made in Ms. Falco’s memory by:
- Joseph and Julia Vassalluzzo

A memorial fund has been established in the name of
**Mrs. Edith Mae Farris**
Donations have been made in Mrs. Farris’ memory by:
- Alison McDowell, Vincennes, IN

A memorial fund has been established in the name of
**Ms. Yeta Finke**
Donations have been made in Ms. Finke’s memory by:
- Arden Down, New York, NY

A memorial fund has been established in the name of
**Ms. Elizabeth Fliss**
Donations have been made in Ms. Fliss’s memory by:
- BAE Systems, Endicott, NY

A memorial fund has been established in the name of
**Mr. Andreas Fokas**
Donations have been made in Mr. Fokas’ memory by:
- Ekaterini Fokas, Astoria, NY

A memorial fund has been established in the name of
**Mrs. Evelyn Forney**
Donations have been made in Mrs. Forney’s memory by:
- Diana Herbe, Cincinnati, OH

A memorial fund has been established in the name of
**Mr. James W. Frejd**
Donations have been made in Mr. Frejd’s memory by:
- Julie Dwyer, Elk Grove Village, IL
- Genie and Gail Borchardt, Arlington Heights, IL

A memorial fund has been established in the name of
**Ms. Elaine Frye**
Donations have been made in Ms. Frye’s memory by:
- James E. Frye, Palestine, TX

A memorial fund has been established in the name of
**Mr. Michael Friedman**
Donations have been made in Mr. Friedman’s memory by:
- Edward and Judith Laszer, Akron, OH

A memorial fund has been established in the name of
**Mr. Sam Friedmam**
Donations have been made in Mr. Friedmam’s memory by:
- Wm. Mark Friedman, Delray Beach, FL

A memorial fund has been established in the name of
**Mr. Jake Edward Froug**
Donations have been made in Mr. Froug’s memory by:
- Ilene Lynch, Plantation, FL

A memorial fund has been established in the name of
**Ms. Jennifer Sharon Gallagher-Welch**
Donations have been made in Ms. Welch’s memory by:
- Sara Edith Gallagher, Dayton, OH

A memorial fund has been established in the name of
**Mr. James “Jim” David Garrick**
Donations have been made in Mr. Garrick’s memory by:
- Gene and Mary Shumate, Mountain 1st Bank & Trust Company
- Gary and Hazel Nabors, Hendersonville, NC
- J. Martin Richey, Boston, MA

A memorial fund has been established in the name of
**Mr. Alfred A. Gianni**
Mr. Gianni’s family made the decision to honor their loved one by establishing this fund to be used for research.
Donations have been made in his memory by:
- David M. Indyke, Short Hills, NJ
- Ajay and Rajni Misra, Andover, NJ
- Maryellen Cheasty, Bangor, PA
- Tom and Sheila Thomas, Monroeville, PA
- Patricia Thomas, Mt. Sinai, NY
- John and Margaret Post, Harford, CT
- Darlene R. Montana, Monroe and Arlene Spiegel, Verona, NJ

A memorial fund has been established in the name of
**Ms. Winnie Green**
Donations have been made in Mrs. Green’s memory by:
- Barbara Yarbrough, Arcadia, CA
A memorial fund has been established in the name of
Mr. Willy Grossman
Donations have been made in Mr. Grossman’s memory by:
Geoffrey and Sandy Goldworm, Jupiter, FL

A memorial fund has been established in the name of
Mr. Jesse Gunder
Donations have been made in Mr. Gunder’s memory by:
Harold C. Ryder
Mechanicsburg, PA

A memorial fund has been established in the name of
Mrs. Ann Leslie Cosenza Hallberg
Donations have been made in Mrs. Hallberg’s memory by:
Christine Cosenza, Branford, CT

A memorial fund has been established in the name of
Ms. Susan Hartman Filippi
Donations have been made in Ms. Filippi’s memory by:
Alessio Filippi, Los Angeles, CA

A memorial fund has been established in the name of
Ms. Patricia Anne Heggemann
Donations have been made in Ms. Heggemann’s memory by:
Steven and Rebecca Heggemann Healthcare Fraud Shield
Employees, Elkridge, MD

A memorial fund has been established in the name of
Mr. James P. Hellenbrand
Donations have been made in Mr. Hellenbrand’s memory by:
Katharine Pease, McFarland, WI

A memorial fund has been established in the name of
Mr. Robert Michael Hillgrove
Donations have been made in Mr. Hillgrove’s memory by:
Carl and Bonnie Hosea
Eric and Alexis Scherer
Erlerang, KY
Muncie, IN
Nancy S. Hewison, West Lafayette, IN

A memorial fund has been established in the name of
Mr. Francis B. Jedd
Donations have been made in Mr. Jedd’s memory by:
Virginia Jedd
Carol Zirk
Blackburg, VA
Waukegan, IL

A memorial fund has been established in the name of
Mrs. Kathryn Karam
Donations have been made in Mrs. Karam’s memory by:
David Karam, Toby, NY

A memorial fund has been established in the name of
Ms. Bunny Kendall
Donations have been made in Ms. Kendall’s memory by:
Irina Blumenthal, Longboat Key, FL

A memorial fund has been established in the name of
Dr. Leonard Kleiman
Donations have been made in Dr. Kleiman’s memory by:
Dr. and Mrs. Geoffrey and Sandy Goldworm, Cherry Hill, NJ

A memorial fund has been established in the name of
Mr. Roy Kussner
Donations have been made in Mr. Kussner’s memory by:
Motorcycle Club of Sun City Carolina Lakes, Indian Land, SC

A memorial fund has been established in the name of
Mr. Patrick B. Laake
Donations have been made in Mr. Laake’s memory by:
Don & Gail Herter
Thomas and Cheri Goforth
Union, NJ
Three Forks, MT

Catherine Goforth
Clarksdale, IN
Joel Lamp and
Rebecca Goforth
Burlingame, CA
Adam Good, Granger, IN
Sandra J. Hollowell
Granger, IN
Maryann Pailet
South Bend, IN
Anne F. Riordan
South Bend, IN
Robert and Linda Howerton, Cartersville, IL

A memorial fund has been established in the name of
Mr. Francis “Al” Lagowski
Donations have been made in Mr. Lagowski’s memory by:
Mr. and Mrs. Edward Ronk
Edison, NJ
John Stack
Basking Ridge, NJ

A memorial fund has been established in the name of
Mrs. Barbara Pilch-Kuett Latchford
Donations have been made in Mrs. Latchford’s memory by:
COFCU Accounting Dept.
Alexandria, VA
Phillip and Charlotte Calif
Vienna, VA

A memorial fund has been established in the name of
Mrs. Edith LeBlanc
Donations have been made in Mrs. LeBlanc’s memory by:
Leopold LeBlanc, Silver Springs, FL

A memorial fund has been established in the name of
Mrs. Arlene Marie Lennox
Donations have been made in Mrs. Lennox’ memory by:
Orville and Judy McKinney, Holiday Island, AR

A memorial fund has been established in the name of
Mr. Barry Levin
Donations have been made in Mr. Levin’s memory by:
Marilyn J. Liehin, Framingham, MA

A memorial fund has been established in the name of
Mr. Ronald Logan
Donations have been made in Mr. Logan’s memory by:
Frank and Michele Cali
Dunmore, PA
Woodloch Pines Inc. and
the Kiesendahl Family
Hawley, PA
Peter J. O’Brien
Mount Pocono, PA
Bob and Dru Scekeres
Mechanicsburg, PA
The Armel Family
Orlando, FL
Kevin and
Dr. Kristen Holliswander
Lake Ariel, PA
East Stroudsburg, PA
A Tribute to Vi

Vi Viva Lee Barnard McDaniels (1922–2012)

Vi was born on October 6, 1922 in Paris, Arkansas, and came to Merced, CA with her Mom, Dad, Brother and Sister in 1931. Vi attended Merced schools and graduated from Merced High School in 1941.

Vi married almost immediately after high school and worked in the retail sector during the war. From this marriage, Vi had a daughter and a son. She also was a volunteer airplane spotter for the then Merced Army Airfield.

Vi trained as a dental assistant and worked in that field during the 50’s and 60’s. That period was before x-ray education and the assistant would stay in the exam room while taking the x-rays. She often mentioned that while taking x-rays on small children, she would hold the film in the child’s mouth while the x-rays were taken.

Vi and I were married in January, 1962, and although she was thirteen years older then I, everyone said and still says, that we were the perfect couple who adored each other. We must have been – as the marriage lasted over fifty years. What a joy she was.

Although we never had children of our own, there was often a baby or young child, who had been neglected in some fashion, in our home for periods of up to a year.

In my profession as a police investigator, we had the opportunity to live in several locations in California, and I retired in San Luis Obispo, CA. Shortly after, we moved back to Merced to be closer to Vi’s family.

In late 2006, Vi was found to have a large aortic aneurysm and, after multiple CT scans and x-rays, and multiple refusals by cardiothoracic surgeons for surgery, she was accepted into a trial at Tucson Francisco Medical Center. That brought about more CT scans and x-rays, and multiple refusals by the hospital “Pink Lady” and a trout fisherman who could really catch them.

She was an antiques collector and a Notary Public who never charged for her services. As the need for the MDs into leukemia.

What else did this amazing woman do in her life time? She painted in oil, landscapes and animals mostly, with cows a big favorite. She worked in ceramics and was a gourmet cook.

She was a first class seamstress who made most of her own clothes and the clothes of whatever child was in the house at the time.

She was the hospital “Pink Lady” and a trout fisherman who could really catch them.

She was a hospital “Pink Lady” and a trout fisherman who could really catch them.

And, in her last years, she knitted over 150 caps for the young cancer patients at Children’s Hospital, Central California “because there was a need.”

That’s what she did.

I will close with a short piece by Edna St. Vincent Millay:

“Where you used to be, there is a hole in the world, which I find myself walking around in the daytime, and falling in at night. I miss you like hell.”

Phil McDaniels, Merced, CA
A memorial fund has been established in the name of
Mr. Ronald H. Martenson
Donations have been made in Mr. Martenson’s memory by:
Jason Sanders, Chicago, IL
Jack and Mary Ridges, Naperville, IL
Carrie Galles, Clive, IA
Catherine Rooney, Chicago, IL
Charles W. Fultz, Lisle, IL
Mel and Rosemarie Di Carlo-Cottone, West Chicago, IL
Carol Welch, Elmhurst, IL

A memorial fund has been established in the name of
Mr. Anthony Massone
Donations have been made in Mr. Massone’s memory by:
Margaret Errico, Stone Ridge, VA

A memorial fund has been established in the name of
Mr. Floyd H. Mattern
Donations have been made in Mr. Mattern’s memory by:
Karen Mattern, Spokane Valley, WA

A memorial fund has been established in the name of
Mrs. Marlene Mauder
Donations have been made in Mrs. Mauder’s memory by:
Robert Coffman, Woodbine, MD
Jon and Cheryl Bear, Burke, VA

A memorial fund has been established in the name of
Mr. Howard McCann
Donations have been made in Mr. McCann’s memory by:
Bernard, Will, Tim, John M, Larry, Kevin, Tom, Todd and Chris Annapolis, MD

A memorial fund has been established in the name of
Mr. Edward L. McCarthy
Donations have been made in Mr. McCarthy’s memory by:
Michael and Kristen McCarthy, Elk Grove, CA
Leslie Hight, Pinehurst, NC

A memorial fund has been established in the name of
Mrs. Maria-Luise “Diane” McDonald
Donations have been made in Mrs. McDonald’s memory by:
Deb Norman, Dick Rank and Mary Kanak, Northfield, MN
Eugene and Christa Tuneck, St. Paul, MN
Rayford, MT

A memorial fund has been established in the name of
Mrs. Ruth Merfeld
Donations have been made in Mrs. Merfeld’s memory by:
Robert and Clare Kreuser, Shakopee, MN
Nancy A. Depaz, Burnsville, MN

A memorial fund has been established in the name of
Mr. Charles R. Mertz
Donations have been made in Mr. Mertz’ memory by:
Richard and Claire Ashby, Lititz, PA
Theresa Guariglia, Galloway, NJ

A memorial fund has been established in the name of
Mrs. Minnie F. Merullo
Donations have been made in Mrs. Merullo’s memory by:
Jeffrey and Elizabeth Bolton, Rochester, MN
Plymouth Rock Assurance of NJ, Berkeley Heights, NJ
Associated Risk Managers of New Jersey, Latham, NY
Brad and Alison Patkochis, Pittstown, NJ

A memorial fund has been established in the name of
Mr. George Milonas
Donations have been made in Mr. Milonas’ memory by:
Jeffrey and Kitty Philips, West Palm Beach, FL
Jeff and Jennifer Czyzewski, Ponte Vedra Beach, FL
Patricia, Judy, Valeria, Nyle, Marriette, Christa, Zabrina, Odetta, Melani, Karen, Vivian, Reggie and Tim, Reggie and Tim, Jacksonville, FL
Joyce Campbell, Newton, NJ
James and Patricia Coates, Apollo Beach, FL
Jack Harris, Lafayette, NJ
Pauline Seretis, Ledgewood, NJ
Steve Baldwin & Eileen Wynn, Hacketstown, NJ

A memorial fund has been established in the name of
Ms. Mary Miyawaki
Donations have been made in Ms. Miyawaki’s memory by:
Mary Miyawaki, Honolulu, HI

A memorial fund has been established in the name of
Mr. Don Moe
Donations have been made in Mr. Moe’s memory by:
Trux Fire Department, Madison, WI
Phyllis L. Lee, Madison, WI

A memorial fund has been established in the name of
Mr. A. Clay Mollman
Donations have been made in Mr. Mollman’s memory by:
Jerry and Joan Kaskowitz, St. Louis, MO
Barbara Steps, St. Louis, MO
Carol Ross, Chesterfield, MO
Roy Pflauff, St. Louis, MO
Phil and Caroline Loughlin, Cambridge, MA
James and Mary Barnes, St. Louis, MO
Walter and Marilyn Shanko, Jacksonville, FL
Julie Linihan, St. Louis, MO
CB and Emily Gehard, St. Louis, MO
Brock M. Lutz, St. Louis, MO
Les and Wendy Bonwik, St. Louis, MO
David E. Stedelin, Centralia, IL
D. M. and Karen Shupp, Tomball, TX
C. W. Holmes, St. Louis, MO
David E. Stedelin, Centralia, IL

A memorial fund has been established in the name of
Mr. Richard B. “Dick” Moorman
Donations have been made in Mr. Moorman’s memory by:
James and Nancy Prussack, Post Falls, ID
Larry and Kiki House, Post Falls, ID
Mitch and Karen Windsor, Anthem, AZ
Thomas Jarrett, Jr., San Antonio, TX
Remmel Miranda, Naperville, IL
Richard and Linda Carney, Salem, OR
Donald and Janet Ruettgers, Stayton, OR
John W. Kronenberger, Central Point, OR
John D. Hillyer, Central Point, OR
Jim and Helen Ruettgers, Stayton, OR
Larry and Judy Harrington, Dennis, CA

A memorial fund has been established in the name of
Mr. Garvin Morris
Donations have been made in Mr. Morris’ memory by:
Art and Bonnie Hosie, Regina, SK, Canada
Ernie and Diane Avram, Regina, Sask, Canada

A memorial fund has been established in the name of
Mrs. Peggy Mozzone
Donations have been made in Mrs. Mozzone’s memory by:
Ron and Ann McKee, Fremont, CA
Cathleen Jones, Atlanta, GA
Harry and Deanna Crews, San Antonio, TX
Joseph Cohen, New York, NY

A memorial fund has been established in the name of
Mr. Hersh Muchnick
Donations have been made in Mr. Muchnick’s memory by:
Irv and Sheila Goldsman, S Burlington, VT
Stewart and Karen Hani, Wynnewood, PA

A memorial fund has been established in the name of
Mr. Nathan
Donations have been made in Mr. Nathan’s memory by:
Albert and Tina Small, Bethesda, MD
A memorial fund has been established in the name of Mrs. Kenneth Nichols
Donations have been made in Mr. Nichols’ memory by:
John E. Nichols, Mills, MA

A memorial fund has been established in the name of Ms. Barbara K. O’Connor
Donations have been made in Ms. O’Connor’s memory by:
Margaret O’Connor, Lewistug, PA

A memorial fund has been established in the name of Mrs. Arlene O’Donnell
Donations have been made in Mrs. O’Donnell’s memory by:
James J. O’Donnell, Ill., Ocean City, NJ

A memorial fund has been established in the name of Mrs. Julie O’Hanlon
Donations have been made in Mrs. O’Hanlon’s memory by:
Catherine Hodge Tampa, FL
Anthony Wickenheiser Joppatowne, MD
Corbin and Marcel Otto Littleton, CO
Brian Schmitt, Pasco, WA
Brown and Caldwell Denver Office, Golden, CO
Dennis and Biv Christine Arcadia, CO
Bill Pedrick Zephyr Cove, NV
Pam Bartholomay Littleton, CO
Michelle Bellows Fort Collins, CO
Linda Armeson Littleton, CO
Mary Garey-Urr Overland Park, KS
Rose Community Foundation Denver, CO
Kevin and Cheryl Bierbaum Anway, CO
Barbara Walz Lakewood, CO
Barbara Walz Lakewood, CO
Patrick Keegan Centennial, CO
Carol S. Heald Denver, CO
Dave Richards (and Brad) Lexington, KY
Joyce A. Tipton Westminster, CO
Dennis E. Stanislav Lakewood, CO
Annandale, CO
Marllyn C. Coombs Denver, CO
Vicki Greivel, Golden, CO
Leslie Tomsic Denver, CO
Shari A. Raymond Morrison, CO
Mark and Marilyn Norwalk Denver, CO
Judy Altenberg Englewood, CO
Lisa Coh, Denver, CO
Edward and Elizabeth Tomsic Denver, CO
New West Physicians (Friends) Golden, CO

A memorial fund has been established in the name of Mr. Chris Okuhara
Donations have been made in Mr. Okuhara’s memory by:
Francis and Jacquelyn Imada, Kailua, Hi

A memorial fund has been established in the name of Dr. Antonio K. Olmedo
Donations have been made in Dr. Olmedo’s memory by:
Marcia Wolf Sparks, MD
Credo Capital Management Baltimore, MD
Omer's Elementary School Faculty & Staff, Baltimore, MD

A memorial fund has been established in the name of Mrs. Cecilia A. Otterbein
Donations have been made in Mrs. Otterbein’s memory by:
Jim and Debbie Madonna, Oak Ridge, NJ

A memorial fund has been established in the name of Mr. Victor J. Palumbo
Donations have been made in Mr. Palumbo’s memory by:
Joan Palumbo Cranford, FL
Victor Andre Palumbo Cranford, FL

A memorial fund has been established in the name of Mr. Donato Parisi
Donations have been made in Mr. Parisi’s memory by:
Renaissance Mers Club, Manchester, N.J

A memorial fund has been established in the name of Mr. Vincenzo “Vince” Pellerito
Donations have been made in Mr. Pellerito’s memory by:
Brett and Mary Feola Beverly Hills, MI
Toby and Kim Theodore Plymouth, MI
Theresa Ziske St. Clair Shores, MI
Gregory and Leah Lefler Chesterfield, MI
Mary Hickey Shelby Twp., MI
Thomas & Denise Wurmlinger Chesterfield, MI
Brian and Judith Meiningter Casco, MI
Frederick & Mary Ann Makinen Agonac, MI
Concetta Pellerito, Richmond, MI

A memorial fund has been established in the name of Mr. Ronald D. Piccianti
Donations have been made in Mr. Piccianti’s memory by:
Matt and Joni Sicking Richardson, TX
Paul Chow, Plano, TX
Robbie Marshall, Dallas, TX
Kevin and Carla Libby Dallas, TX
Diane Menza, Oak Park, IL
Libby York, Dallas, TX

A memorial fund has been established in the name of Mrs. Lovella Ann Hayes Ralstin
Donations have been made in Mrs. Ralstin’s memory by:
Robin Rolston Irvine, CA
Royanne Hensley, Houston, TX
Dr. Frost, Dr. Saltard and the Pulmonary Hypertension Staff Houston, TX

A memorial fund has been established in the name of Mr. Emel (Bill) Rawls, Jr.
Donations have been made in Mr. Rawls’ memory by:
Therese Kolbacher Centerville, OH
Betty J. Saaster Locust Grove, VA
Barbara Miller Locust Grove, VA

A memorial fund has been established in the name of Mr. Johnny Ramos
Donations have been made in Mr. Ramos’ memory by:
Iris Murzir Wood-Ridge, NJ

A memorial fund has been established in the name of Mr. Jon Arthur Reuscher
Donations have been made in Mr. Reuscher’s memory by:
Colleagues of Mark Batarseh Reston, VA
David and Cathy Chase Falls Church, VA
Leanne Wells Laurel, MD

A memorial fund has been established in the name of Mr. Jerome Richter
Donations have been made in Mr. Richter’s memory by:
Geoffrey and Sandy Goldworm, Cherry Hill, NJ

A memorial fund has been established in the name of Mr. Edward J. Ruhe
Donations have been made in Mr. Ruhe’s memory by:
Justin Schaefer Meridianville, AL
Jerry and Kay Powoaze Terre Haute, IN
J and Goldie Hicks, Brazil, IN
Thomas C. Martin Rockville, TN
Shawn and Chris Becker Ferdinand, IN

A memorial fund has been established in the name of Mr. Rudy Rodriguez, Jr.
Donations have been made in Mr. Rodriguez’ memory by:
Edward Main, Houston, TX
Ann Morgan, Houston, TX

A memorial fund has been established in the name of Mrs. Mary Mills Hendersonville, TN
A memorial fund has been established in the name of Dr. Charlie and Betty Hayes Coffeyville, KS
A memorial fund has been established in the name of Gloria Buchanan Seabrook, TX
A memorial fund has been established in the name of Mr. Chris Okuhara
Donations have been made in Mr. Okuhara’s memory by:
Francis and Jacquelyn Imada, Kailua, Hi
A memorial fund has been established in the name of Mr. Abraham (Abe) Rosenthal
Donations have been made in Mr. Rosenthal’s memory by:
Martin and Deborah Segal, Suga Land, TX

A memorial fund has been established in the name of Mr. Paul Rosinski
Donations have been made in Mr. Rosinski’s memory by:
Ed and Carole Johnson, Great Mills, MD

A memorial fund has been established in the name of Mrs. Sue Schieres
Donations have been made in Mrs. Schieres’ memory by:
Robert Schieres, Centerville, OH

A memorial fund has been established in the name of Mr. Fred E. Schmalz-Riedt
Donations have been made in Mr. Schmalz-Riedt’s memory by:
Yvette Schmalz-Riedt, Earlysville, VA

A memorial fund has been established in the name of Mr. Frank Samuels
Donations have been made in Mr. Samuels’ memory by:
Carol Kosberg, Palm Beach, FL

A memorial fund has been established in the name of Mr. Philip J. Selch
Donations have been made in Mr. Selch’s memory by:
Konnie Selch, Centennial, CO

A memorial fund has been established in the name of Lt. Col. (ret) Robert G. Shain
Donations have been made in Lt. Col. Shain’s memory by:
Lisa LaFontaine, Washington, DC
Larry Wiesniak, U. S. Army
Executive Flight Detachment
College Station, TX
Claude and Toni Bard
Pueblo West, CO
Rox Shain, Parker, CO
Art and Deb Pescatore
Hartsille, PA
Harry Charles Lynn
McLean, VA

A memorial fund has been established in the name of Mrs. Suzanne Shultz
Donations have been made in Mrs. Shultz’ memory by:
Velva Stern
Lake Forest Park, WA
Lawrence and Rosanna Kahn
Redmond, WA
Don and Jean Krisher
Bellevue, WA
Ronald and Henrietta Klein
Redmond, WA
Larry Jacobs, Leawood, KS
Andy and Carol Harris
Mercer Island, WA

A memorial fund has been established in the name of Mr. Robert “Dewey” Smart
Donations have been made in Mr. Smart’s memory by:
Ron and Kim Thomason, Franklin, TN

A memorial fund has been established in the name of Mr. Kenneth Larry Smith
Donations have been made in Mr. Smith’s memory by:
Barry Rynt, Boca Raton, FL

A memorial fund has been established in the name of Mr. Bob Spear
Donations have been made in Mr. Spear’s memory by:
Vic Ariss, Irving, TX

A memorial fund has been established in the name of Mrs. Virginia R. Stephenson
Donations have been made in Mrs. Stephenson’s memory by:
Howard Stephenson, Lakeside, MT

A memorial fund has been established in the name of Mr. Billie Sterlie
Donations have been made in Mr. Sterlie’s memory by:
David Sterlie, Louisville, KY

A memorial fund has been established in the name of Mr. Paul Stutzman
Donations have been made in Mr. Stutzman’s memory by:
Jerry, Gae and Kevin
Monaghan, Surprise, AZ
Tricia Cowles
Westminster, CA

A memorial fund has been established in the name of Mr. Robert Sudimack
Donations have been made in Mr. Sudimack’s memory by:
Marjorie Sudimack, Warren, OH

A memorial fund has been established in the name of Mr. Satoru “Sat” Sugiura
Donations have been made in Mr. Sugiura’s memory by:
Kathy (Sakaguchi) Manuardt
Esk Grove, CA
Janet T. Tashima, Turlock, CA
Gaye Sakaguchi-Yee
Glendale, CA
Ed & Jodi Felt, Turlock, CA

A memorial fund has been established in the name of Mr. Franklin Taylor, III
Donations have been made in Mr. Taylor’s memory by:
Craig Follis
Richmond, VA
Richard and Sallie Cross
Richmond, VA
Doug and Gloria Wetmore
Middletown, VA
Deborah Maury, Maidens, VA
Lee and Pattie Bourne
Montpelier, VA
Elliot and Tim Meiril
Richmond, VA
Mr. and Mrs. Edward B. Evans
Mechanicsville, VA
Linda F. Young, Glen Allen, VA
Robert and Pat Hendrick
Richmond, VA
Belle Ann Apodaca
Sandston, VA
James Warren Peaman
Richmond, VA
Parker and Beverly Dillard
Richmond, VA
Spectrum of Richmond, Inc.
Richmond, VA
Indiana Amateur Softball Assoc., Bloomington, IN
George and Joy Baynes
Henrico, VA

A memorial fund has been established in the name of Mr. Landon “Butch” Scott Temple, Jr.
Donations have been made in Mr. Temple’s memory by:
VAGE, Alberta, VA

A memorial fund has been established in the name of Mrs. Lucy Terranova
Donations have been made in Mrs. Terranova’s memory by:
Art and Sue Smith
Norristown, PA
Paul and Betty Vagedes
Fairfield Bay, AR
Linda, Michelle, Laura, Enka, Emma, Nicole, Ted and Matt
Glenside, PA
Warren and Linda Cohn
Norristown, PA
Russ and Joan Thayer
Troy, OH
Gerard and Patricia Guffrida
Eagleville, PA
Benjamin and Lillian Risilia
Philadelphia, PA
Terry and Dolores Hertzberg
West Berlin, NJ
Marie Riddito
Philadelphia, PA
Dolores Boccuti, Glenobra, NJ

A memorial fund has been established in the name of Mr. Robert and Jayne Ukoop
Richmond, VA
Jimmie and Nancy Call
Custom Ornamental Iron, Inc.
Glen Allen, VA
Grace E. Kulick
Mechanicsville, VA
John and Jeannine Miller
Hopewell, VA
The 2012 Granger League
Middletown, VA
Barbara I. Young
Mechanicsville, VA
Earline B. Bayless
Richmond, VA
William W. King
Norfolk, VA
Barbara G. Whitecotton
Montpelier, VA
James F. Robinson
St. Cloud, FL
Virginia Faulkner
Richmond, VA
William J. Edwards
Richmond, VA
Sandra L. Clements
Hampton, VA
Janice R. Miller
Doswell, VA
Nancy S. Boyer
Richmond, VA
James & Savilla Pleasants
Deltaville, VA

Carmen J. Shortt
Richmond, VA
Barry Hedges
Richmond, VA
Adams, Jenkins and Cheatham
Midlothian, VA
Dave and Wendy Ames
Mechanicsville, VA
Allen Taylor, Richmond, VA
Bonnie and Polly Culley
Midlothian, VA
Elizabeth A. Gallanis
Rochester, MN
Vipers Softball Club
for Veterans
Alexandria, VA
A. E. Robertson, Jr.
Montgomery, AL
Mitch and Sue Forrester
Kilmarnock, VA
Steve and Martha Stokes
Glen Allen, VA
Anne N. M. Johnson
Midlothian, VA
Robert S. Brockmeier, Jr.
Hennico, VA
W. R. and Joan Branch
Ashland, VA
Base Crawlers, Full Force
Junton & Williams
Richmond, VA
A memorial fund has been established in the name of
Mrs. Doris Kjersgaard Thomas
Donations have been made in Mrs. Thomas’s memory by:
Irene K. Roberts
Broomfield, CO
Lisa Severino
Cherry Hill, NJ

A memorial fund has been established in the name of
(Lt. Col. Ret.) USAF Timothy Louis Thomas
Donations have been made in Lt. Col. Thomas’ memory by:
Ann M. Thomas, Wichita Falls, TX

A memorial fund has been established in the name of
Ms. Margaret D. (Peggy) Timmons
Donations have been made in Mrs. Timmons’s memory by:
Dorothy D. Zeek
Sumter, SC
Tommie and Cindy Watts
Creston, SC

A memorial fund has been established in the name of
Mrs. Faith Darlene Todgami
Donations have been made in Mrs. Todgami’s memory by:
Nino M. Northbrooke, IL
Dale R. Tanis
Geneva, IL
Mike and Rhonda Whitney
Taylor Ridge, IL

A memorial fund has been established in the name of
Mrs. Jeanette Toth
Donations have been made in Mrs. Toth’s memory by:
Joseph Toth
Manalapan, NJ
Donna, Dave, Davey Bunton
Arlington, VA

A memorial fund has been established in the name of
Ms. Barbara Fayette Towne
Donations have been made in Ms. Towne’s memory by:
Angelo and Lynn Pizzagalli
South Burlington, VT
John and Nancy Riksin
Unisalde, NY
Tom McCabe
South Burlington, VT
“Operations Department” of PC Construction Company
Essex Junction, VT
James and Judy Pizzagalli
Sheffield, VT
PC Construction Company
South Burlington, VT
Alan Towne
Winthrop, MA
James J. Handy, CLU
Burlington, VT

A memorial fund has been established in the name of
Mrs. Anita Tremaroli
Donations have been made in Mrs. Tremaroli’s memory by:
Frank and Terri Troic
East Meadow, NY
Nick and Ariene Delmonaco
Edison, NJ
Steve and Marianne Tremaroli
Huntington, NY
Charles and Marie Breussa
Wyckoff, NJ
Paula M. Danese
East Meadow, NY

A memorial fund has been established in the name of
Mr. Paul M. Vukelic
Donations have been made in Mr. Vukelic’s memory by:
Alan and Cynthia Stoeckel
and Family, Palatine, IL
Jeanette Kiehl
Palatine, IL

A memorial fund has been established in the name of
Mr. Thomas Earl Walrath
Donations have been made in Mr. Walrath’s memory by:
Larry and Stephanie Seiple
Oakland, CA

A memorial fund has been established in the name of
Mr. Richard (Rick) Warner
Donations have been made in Mr. Warner’s memory by:
Donald and Susan Kah
Hollywood, FL
Mike and Barbara Santomaso
Hollywood, FL
Wade and Lindsey Cox
Oviedo, FL

A memorial fund has been established in the name of
Mr. Jim Warren
Donations have been made in Mr. Warren’s memory by:
Carolyn Warren
St. Petersburg, FL

A memorial fund has been established in the name of
Ms. Selma Weiner
Donations have been made in Ms. Weiner’s memory by:
Bert and Marcii Blicher
Delray Beach, FL
Luxury Partners LLC
Delray Beach, FL

A memorial fund has been established in the name of
Ms. Alicia White
Donations have been made in Ms. White’s memory by:
Lawrence and Melinda Zack
London, Ontario, Canada

A memorial fund has been established in the name of
Ms. Nellie White
Donations have been made in Ms. White’s memory by:
Angelo and Rose Staikos, Hazet, NJ

A memorial fund has been established in the name of
Mr. Thomas Earl Walrath
Donations have been made in Mr. Walrath’s memory by:
Larry and Stephanie Seiple
Oakland, CA

A memorial fund has been established in the name of
Mr. Richard (Rick) Warner
Donations have been made in Mr. Warner’s memory by:
Donald and Susan Kah
Hollywood, FL
Mike and Barbara Santomaso
Hollywood, FL
Wade and Lindsey Cox
Oviedo, FL

A memorial fund has been established in the name of
Mr. Jim Warren
Donations have been made in Mr. Warren’s memory by:
Carolyn Warren
St. Petersburg, FL

A memorial fund has been established in the name of
Ms. Selma Weiner
Donations have been made in Ms. Weiner’s memory by:
Bert and Marcii Blicher
Delray Beach, FL
Luxury Partners LLC
Delray Beach, FL

A memorial fund has been established in the name of
Ms. Alicia White
Donations have been made in Ms. White’s memory by:
Lawrence and Melinda Zack
London, Ontario, Canada

A memorial fund has been established in the name of
Ms. Nellie White
Donations have been made in Ms. White’s memory by:
Angelo and Rose Staikos, Hazet, NJ

Suzanne Fleischman Memorial Fund for Patient Advocacy
A fund has been established by the MDS Foundation in memory of Suzanne Fleischman. Contributions may be sent to the Foundation with a notation designating the Suzanne Fleischman Memorial Fund for Patient Advocacy.

Roslyn Raney, Menlo Park, CA
Fay Wanetick, Pittsburgh, PA

A memorial fund has been established in the name of
Mr. N. Eugene “Whitey” White
Donations have been made in Mr. White’s memory by:
Daryl E. Johnson
Cameron, IL
Mary H. Turner
Roseville, IL
James M. and
Willa Deane Moore
Knoxville, IL

A memorial fund has been established in the name of
Mr. Richard (Rick) Warner
Donations have been made in Mr. Warner’s memory by:
Donald and Susan Kah
Hollywood, FL
Mike and Barbara Santomaso
Hollywood, FL
Wade and Lindsey Cox
Oviedo, FL

A memorial fund has been established in the name of
Mr. Jim Warren
Donations have been made in Mr. Warren’s memory by:
Carolyn Warren
St. Petersburg, FL

A memorial fund has been established in the name of
Ms. Selma Weiner
Donations have been made in Ms. Weiner’s memory by:
Bert and Marcii Blicher
Delray Beach, FL
Luxury Partners LLC
Delray Beach, FL

A memorial fund has been established in the name of
Ms. Alicia White
Donations have been made in Ms. White’s memory by:
Lawrence and Melinda Zack
London, Ontario, Canada

A memorial fund has been established in the name of
Ms. Nellie White
Donations have been made in Ms. White’s memory by:
Angelo and Rose Staikos, Hazet, NJ

A memorial fund has been established in the name of
Mr. Neal Eddins Wingfield
Donations have been made in Mr. Wingfield’s memory by:
E. Joan Rollins
Oklahoma City, OK
Rev. and Mrs. Robert Shields
New Bern, NC

A memorial fund has been established in the name of
Mrs. Joan Zimetbaum
Donations have been made in Mrs. Zimetbaum’s memory by:
Nancy Strauss
Scarborough, NY

A memorial fund has been established in the name of
Mr. Fred Zucker
Donations have been made in Mr. Zucker’s memory by:
Kenneth Richieri
New York, NY
Lee Riffaterre
New York, NY
**A Living Endowment**

Many families are affected by living with the reality of MDS. There is an extraordinary way to contribute to the MDS Foundation and support our mission of working as a resource for patients, families, and healthcare professionals.

A commitment to donate to the Foundation on occasions of loss, birthdays, and anniversary remembrances can be made. Honor your friends or family members on these occasions with a donation, and the MDS Foundation will send an acknowledgment to the recipient, recognizing the occasion.

<table>
<thead>
<tr>
<th>A Living Endowment donation has been made in honor of:</th>
<th>A Living Endowment donation has been made in honor of:</th>
<th>Living Endowment donations have been made in honor of:</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Seth Cohen</strong></td>
<td><strong>Joan Kane</strong></td>
<td><strong>Morey Storck</strong></td>
</tr>
<tr>
<td>This donation was submitted by:</td>
<td>This donation was submitted by:</td>
<td>These donations were submitted by:</td>
</tr>
<tr>
<td>Geoffrey &amp; Sandy Goldworm, Jupiter, FL</td>
<td>Betty Jo Vail</td>
<td>Newt &amp; Lois Alterman, Tarrytown, NY</td>
</tr>
<tr>
<td></td>
<td>Lititz, PA</td>
<td>Herb &amp; Gloria Portnoy, Briarcliff Manor, NY</td>
</tr>
<tr>
<td>A Living Endowment donation has been made in honor of:</td>
<td>A Living Endowment donation has been made in honor of:</td>
<td>Mel and Dr. Cynthia Chesner, Tarrytown, NY</td>
</tr>
<tr>
<td><strong>Jonathan Cohn</strong></td>
<td><strong>Mahaveer Prabhakar</strong></td>
<td>Rita Wexler, Tarrytown, NY</td>
</tr>
<tr>
<td>This donation was submitted by:</td>
<td>This donation was submitted by:</td>
<td></td>
</tr>
<tr>
<td>Dr. Robert Cohn and Ruth Cohn Family Foundation</td>
<td>Gloria Schwartz</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Woodland Hills, CA</td>
<td></td>
</tr>
<tr>
<td>A Living Endowment donation has been made in honor of:</td>
<td>A Living Endowment donation has been made in honor of:</td>
<td></td>
</tr>
<tr>
<td><strong>Robert W. Cook</strong></td>
<td><strong>Arnold Schwartz</strong></td>
<td><strong>Diana Termine</strong></td>
</tr>
<tr>
<td>This donation was submitted by:</td>
<td>This donation was submitted by:</td>
<td>These donations were submitted by:</td>
</tr>
<tr>
<td>Suzanne Demartini, Plymouth, MA</td>
<td>Gloria Schwartz</td>
<td>Ronald and Linda Jaffe, Aurora, IL</td>
</tr>
<tr>
<td>A Living Endowment donation has been made in honor of:</td>
<td></td>
<td>George Zander, Palos Hills, IL</td>
</tr>
<tr>
<td><strong>Gerald Duehr</strong></td>
<td></td>
<td>Patricia Adesso, Bloomingdale, IL</td>
</tr>
<tr>
<td>This donation was submitted by:</td>
<td></td>
<td>Carol Olivo, Elmwood Park, IL</td>
</tr>
<tr>
<td>Thomas Means, New Berlin, WI</td>
<td></td>
<td>Dave and Rhonda Meyer, Saint Charles, IL</td>
</tr>
<tr>
<td>Living Endowment donations have been made in honor of:</td>
<td></td>
<td>Scott Termine, Plainfield, IL</td>
</tr>
<tr>
<td><strong>Benny F. Evatt</strong></td>
<td></td>
<td>Jean Laumann, Naperville, IL</td>
</tr>
<tr>
<td>These donations were submitted by:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>June M. Evatt, Pendleton, SC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maureen Maughan, Cranbury, NJ</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peggy Cherkasky, Pittsford, NY</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A Living Endowment donation has been made in honor of:</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Irv Glickman</strong></td>
<td></td>
<td>A Living Endowment donation has been made in honor of:</td>
</tr>
<tr>
<td>This donation was submitted by:</td>
<td></td>
<td><strong>Remo Tersolo</strong></td>
</tr>
<tr>
<td>Geoffrey and Sandy Goldworm, Jupiter, FL</td>
<td></td>
<td>This donation was submitted by:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Susan Urban, Oceanside, CA</td>
</tr>
<tr>
<td>A Living Endowment donation has been made in honor of:</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Angelo Staikos</strong></td>
<td></td>
<td>Ronald J. Vanskiver,</td>
</tr>
<tr>
<td>This donation was submitted by:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Angelo and Rose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hazlet, NY</td>
<td></td>
<td>Helen Vanskiver, Nottingham, MD</td>
</tr>
</tbody>
</table>

**Living Endowment donations have been made in honor of:**

<table>
<thead>
<tr>
<th>Morey Storck</th>
</tr>
</thead>
<tbody>
<tr>
<td>Newt &amp; Lois Alterman, Tarrytown, NY</td>
</tr>
<tr>
<td>Herb &amp; Gloria Portnoy, Briarcliff Manor, NY</td>
</tr>
<tr>
<td>Mel and Dr. Cynthia Chesner, Tarrytown, NY</td>
</tr>
<tr>
<td>Rita Wexler, Tarrytown, NY</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Diana Termine</th>
</tr>
</thead>
<tbody>
<tr>
<td>These donations were submitted by:</td>
</tr>
<tr>
<td>Ronald and Linda Jaffe, Aurora, IL</td>
</tr>
<tr>
<td>George Zander, Palos Hills, IL</td>
</tr>
<tr>
<td>Patricia Adesso, Bloomingdale, IL</td>
</tr>
<tr>
<td>Carol Olivo, Elmwood Park, IL</td>
</tr>
<tr>
<td>Dave and Rhonda Meyer, Saint Charles, IL</td>
</tr>
<tr>
<td>Scott Termine, Plainfield, IL</td>
</tr>
<tr>
<td>Jean Laumann, Naperville, IL</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Remo Tersolo</th>
</tr>
</thead>
<tbody>
<tr>
<td>This donation was submitted by:</td>
</tr>
<tr>
<td>Susan Urban, Oceanside, CA</td>
</tr>
</tbody>
</table>

| Ronald J. Vanskiver,                                      |
|                                                        |
| Helen Vanskiver, Nottingham, MD                          |
MDS Foundation Information

The Foundation’s Board of Directors

John M. Bennett, MD
Professor of Medicine, Emeritus
Laboratory Medicine and Pathology
University of Rochester Medical Center
Rochester, New York, U.S.A.

Mario Cazzola, MD
Professor of Hematology
University of Pavia School of Medicine
Head, Department of Hematology
Fondazione IRCCS Policlinico San Matteo
Pavia, Italy

Erin Demakos, RN, CCRN
Administrative Director
Myelodysplastic Disease Center
and MPD Program
Mount Sinai School of Medicine
New York, New York, U.S.A.

Theo J.M. de Witte, MD, PhD
Professor of Hematology
University Medical Center
Nijmegen St. Radboud
Nijmegen, The Netherlands

Pierre Fenaux, MD
Professor of Hematology
Hôpital Avicenne,
University Paris 13
Bobigny, France

Peter L. Greenberg, MD
Professor of Medicine/Hematology
Stanford University
School of Medicine
Stanford, California, U.S.A.

Eva Hellström-Lindberg, MD, PhD
Associate Professor of Hematology
Karolinska Institutet
Institution for Medicine
Huddinge University Hospital
Stockholm, Sweden

Sandra E. Kurtin, RN, MS,
AOCN, ANP-C
Hematology/Oncology Nurse Practitioner
The University of Arizona Cancer Center
Adjunct Clinical Assistant Professor of Nursing
Clinical Assistant Professor of Medicine
University of Arizona
Tucson, Arizona, U.S.A.

Alan F. List, MD
President and CEO
and Frank and Carol Morsani
Endowed Chair
H. Lee Moffitt Cancer Center
& Research Institute
Tampa, Florida, U.S.A.

Silvia M.M. Magalhães, MD, PhD
Professor of Clinical Medicine—Hematology
Federal University of Ceará
Hospital Universitário Walter Cantídio
Ceará, Brazil

Yasushi Miyazaki, MD
Chief, Dept. of Hematology
Nagasaki University Graduate School of Biomedical Sciences
Atomic Bomb Disease Institute
Nagasaki, Japan

John Molle, CPA
JRM Financial Associates, LLC
Flemington, New Jersey, U.S.A.

Ghulam J. Mufti, DM, FRCP, FRCPath
Professor of Haematology and Head of Department
Haematological Medicine
King’s College London & King’s College Hospital
London, United Kingdom

Charlotte M. Niemeyer, MD
Professor of Pediatrics
University Children’s Hospital
Freiburg, Germany

Stephen D. Nimer, MD, Chairman
The MDS Foundation, Inc.
Director, Sylvester Comprehensive Cancer Center
Professor of Medicine, Biochemistry & Molecular Biology
University of Miami Miller School of Medicine
Miami, Florida, U.S.A

David P. Steensma, MD
Associate Professor
Department of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts, U.S.A.

Robert J. Weinberg, Esq.
Pepper Hamilton LLP
Philadelphia, Pennsylvania, U.S.A.

Emeritus Member
Franz Schmalzl, MD
Innsbruck, Austria

Become a Member

The MDS Foundation would like to have you as a member. Membership is $50 a year for physicians and other professionals. Patients, their families, and others interested in MDS may join at the reduced rate of $35.

Membership benefits include issues of the MDS News, a special subscription rate of $135.00 for Leukemia Research (a substantial discount from the current institutional subscription rate of $2,373), and the worldwide Centers of Excellence patient referral service.

Please visit us at: www.mds-foundation.org.